<SEC-DOCUMENT>0001493152-21-020826.txt : 20210820
<SEC-HEADER>0001493152-21-020826.hdr.sgml : 20210820
<ACCEPTANCE-DATETIME>20210820164617
ACCESSION NUMBER:		0001493152-21-020826
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20210820
DATE AS OF CHANGE:		20210820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257558
		FILM NUMBER:		211194375

	BUSINESS ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)<BR>
Registration No. 333-257558</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><BR>
(To Prospectus dated July 9, 2021)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>$30,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 58px; width: 340px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an equity distribution agreement (the &ldquo;Sale Agreement&rdquo;) with Oppenheimer &amp; Co. Inc. (&ldquo;Oppenheimer&rdquo;
or &ldquo;Sales Agent&rdquo;), dated August 20, 2021, relating to the sale of shares of our common stock, par value $0.0001 per
share (the &ldquo;common stock&rdquo;), offered by this prospectus supplement. In accordance with the terms of the Sale Agreement, we
may offer and sell shares of our common stock, having an aggregate offering price of up to $30,000,000 from time to time through Oppenheimer,
acting as agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our common stock, if any, under this prospectus supplement may be made by any method deemed to be an &ldquo;at the market offering&rdquo;
as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), including sales
made directly on or through the Nasdaq Capital Market or any other existing trading market for our common stock or, if expressly authorized
by us, in privately negotiated transactions. Oppenheimer is not required to sell any specific amount, but will act as our sales agent
using commercially reasonable efforts, consistent with its normal trading and sales practices. There is no arrangement for funds to be
received in any escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oppenheimer
will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price per share sold under the Sale Agreement.
See &ldquo;Plan of Distribution&rdquo; beginning on page S-9 for additional information regarding the compensation to be paid to Oppenheimer.
In connection with the sale of the common stock on our behalf, Oppenheimer will be deemed to be an &ldquo;underwriter&rdquo; within the
meaning of the Securities Act and the compensation of Oppenheimer will be deemed to be underwriting commissions or discounts. We also
have agreed to provide indemnification and contribution to Oppenheimer with respect to certain liabilities, including liabilities under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the trading symbol &ldquo;PCSA.&rdquo; On August 13, 2021, the last reported
sale price of our common stock on the Nasdaq Capital Market was $5.41 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Investing
in our common stock involves risks. See &ldquo;Risk Factors&rdquo; beginning on page S-9 of this prospectus supplement and in our Annual
Report on Form 10-K for the year ended December 31, 2020 and our other periodic reports filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;), and incorporated by reference herein.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of
this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Oppenheimer
&amp; Co.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is August 20, 2021.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="text-transform: uppercase"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-iii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_001">ABOUT
    THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_002">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_003">PROSPECTUS
    SUMMARY</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_004">RISK
    FACTORS</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_005">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_006">DESCRIPTION
    OF SECURITIES</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_007">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_001">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_002">EXPERTS
    </A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_003">WHERE
    YOU CAN FIND MORE INFORMATION </A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_004">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
further information regarding us and our financial information, you should refer to our recent filings with the SEC. See the sections
titled &ldquo;Where You Can Find More Information&rdquo; in the accompanying prospectus &ldquo;Incorporation of Certain Documents by
Reference&rdquo; in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus
or any applicable free writing prospectus in making a decision about whether to invest in our common stock. We have not, and the Sales
Agent has not, authorized any other person to provide you with different or additional information. If anyone provides you with different
or additional information, you should not rely on it. This prospectus supplement and the accompanying prospectus do not constitute an
offer to sell, or a solicitation of an offer to purchase, any securities in any jurisdiction where it is unlawful to make such an offer
or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, any applicable
free writing prospectus and the documents incorporated by reference herein or therein is accurate only as of their respective dates or
on the date or dates which are specified in these documents. Our business, financial condition, liquidity, results of operations and
prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The
distribution of this prospectus supplement and the accompanying prospectus and the offering of our common stock in certain jurisdictions
may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying
prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution
of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying
prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities
offered by this prospectus supplement and the accompanying prospectus to or by any person in any jurisdiction in which it is unlawful
for such person to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><A NAME="a_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT
THIS PROSPECTUS SUPPLEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is in two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes
the specific terms of this offering. The second part, the accompanying prospectus dated July 9, 2021, gives more general information,
some of which may not apply to this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent the information contained in this prospectus supplement differs or varies from the information contained in the accompanying
prospectus or documents incorporated by reference, the information in this prospectus supplement will supersede such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement does not contain all of the information that is important to you. You should read the accompanying prospectus as
well as the documents incorporated by reference in this prospectus supplement and the accompanying prospectus. See &ldquo;Incorporation
of Certain Documents by Reference&rdquo; in this prospectus supplement and &ldquo;Where You Can Find More Information&rdquo; in the accompanying
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa&rsquo;s
name and logo are either registered trademarks or trademarks of Processa Pharmaceuticals, Inc. in the United States and/or other countries.
All other trademarks, service marks or other tradenames appearing in this prospectus supplement and the accompanying prospectus are the
property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise mentioned or unless the context requires otherwise, all references in this prospectus supplement to the &ldquo;Company&rdquo;,
&ldquo;Processa&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo; or similar references mean Processa Pharmaceuticals, Inc.,
a Delaware corporation, and its wholly owned subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein contain certain &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and
Section 21E of the Exchange Act. All statements other than statements of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
&ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of these words or other comparable terminology. We have based these forward-looking
statements on our current expectations and projections about future events and trends that we believe may affect our financial condition,
results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions,
the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain funding for our future operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 pandemic on our business, operations or ability to obtain funding;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential market size, opportunity and growth potential for our product candidates, if approved;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize our product candidates,
    if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to advance product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit and enroll suitable patients in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory filings and approvals and other product development
    objectives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement of our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of our product candidates by physicians, patients, third-party payors and others in the medical
    community, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model, strategic plans for our business, product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors and our industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements reflect our management&rsquo;s expectations or predictions of future conditions, events or results based on various assumptions
and management&rsquo;s estimates of trends and economic factors in the markets in which we are active, as well as our business plans.
They are not guarantees of future performance. By their nature, forward-looking statements are subject to risks and uncertainties. Our
actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated
in these forward-looking statements. There are a number of factors that could cause actual conditions, events or results to differ materially
from those described in the forward-looking statements contained in this prospectus supplement, the accompanying prospectus and the documents
incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
an additional discussion under &ldquo;Risk Factors&rdquo; in any applicable prospectus supplement and any related free writing prospectus,
and in our most recent Annual Report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. These forward-looking statements
are representative only as of the date they are made, and we undertake no obligation to update any forward-looking statement as a result
of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="a_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 35.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that effects survival or the patient&rsquo;s quality of life and for which few
or no treatment options currently exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a development company, not a discovery company, that seeks to identify and develop drugs for patients who need better treatment options
than presently exist for their medical condition. In order to increase the probability of development success, our pipeline only includes
drugs which have previously demonstrated some efficacy in the targeted population or a drug with very similar pharmacological properties
has been shown to be effective in the population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
screening criteria for identifying and selecting new candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    an unmet or underserved clinical need,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    demonstrated evidence of efficacy in humans, and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">leveraging
    our regulatory science approach to improve the probability for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
many instances, these clinical candidates have significant pre-clinical and clinical data that we may leverage to high value inflection
points while de-risking the programs and adding in optionality to potential future indications. Our regulatory science approach developed
by our team over decades of work with regulatory authorities attempts to balance the &ldquo;risk/benefit&rdquo; equation to identify
a regulatory path with lower risk and shorter timelines to deliver urgent or unmet medical needs to patients, physicians and caregivers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline includes drugs that (i) already have clinical proof-of-concept data demonstrating the desired pharmacological activity in humans
or, minimally, clinical evidence in the form of case studies or clinical experience demonstrating the drug or a similar drug pharmacologically
can successfully treat patients with the targeted indication; (ii) target indications for which the FDA believes might allow a single
positive pivotal study demonstrating efficacy provides enough evidence that the clinical benefits of the drug and its approval outweighs
the risks associated with the drug or the present standard of care (e.g., some orphan indications, many serious life-threatening conditions,
some serious quality of life conditions); and/or (iii) target indications where the prevalence of the condition and the likelihood of
patients enrolling in a study meet the desired time-frame to demonstrate that the drug can, at some level, treat or potentially treat
patients with the condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
advance our mission, we have assembled an experienced and successful development team with a track record of drug approvals and successful
exits. Our team is experienced in developing drug products through all principal regulatory tiers from IND enabling studies to NDA submission.
The combined scientific, development and regulatory experience of our team members has resulted in more than 30 drug approvals by the
FDA, over 100 meetings with the FDA and involvement with more than 50 drug development programs, including drug products targeted to
patients who have an unmet medical need. Although we believe that the skills and experience of our team members in drug development and
commercialization is an important indicator of our future success, the past successes of our team members in developing and commercializing
pharmaceutical products does not guarantee that they will successfully develop and commercialize drugs in our current pipeline. In addition,
the growth in revenues of companies at which our executive officers and directors served in was due to many factors and does not guarantee
that they will successfully operate or manage us or that we will experience similar growth in revenues, even if they continue to serve
as executive officers and/or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate meaningful revenue from any products depends on our ability to out-license the drugs before or after we obtain FDA
NDA approval. Even if our products are authorized and approved by the FDA, it should be noted that the products must still meet the challenges
of successful marketing, distribution and consumer acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Drug Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical pipeline (shown below) summarizes each drug, organized by the therapeutic area (i.e., non-oncology and oncology) and stage of
development (i.e., Preclinical to Phase 3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have five drugs: four in various stages of clinical development (PCS499, PCS12852, PCS3117, and PCS6422) and one in nonclinical
development (PCS11T). We group our drugs into non-oncology (PCS499 and PCS12852) and oncology (PCS3117, PCS6422 and PCS11T). A summary
of each of our five drugs is provided below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    most advanced product candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline
    (PTX or Trental&reg;). We completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica
    (NL) in late 2020, and in May 2021 we enrolled the first patient in our Phase 2B trial for the treatment of ulcerative NL. We expect
    to complete our interim analysis of the Phase 2B trial in the first half of 2022 (1H&rsquo;22); complete the trial in the second
    half of 2022 (2H&rsquo;22); and, depending on the results, begin a pivotal Phase 3 trial in 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
    is a highly specific and potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
    and gastrointestinal motility. We are planning on submitting an IND application in the third quarter of 2021 (3Q&rsquo;21) for the
    treatment of gastroparesis based on our pre-IND communications with the FDA. We anticipate beginning to enroll patients for a Phase
    2A trial in the 1H&rsquo;22, with expected completion in the first half of 2023 (1H&rsquo;23). </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS3117,
    which we licensed in June 2021, is a cytosine analog, similar to gemcitabine (Gemzar&reg;) but different enough in chemical structure
    that some patients are more likely to respond to PCS3117 than gemcitabine. We are developing potential biomarkers to predict which
    patients are more likely to respond to PCS3117 than gemcitabine and other chemotherapy agents to provide a more targeted, precision
    medicine approach to the treatment of pancreatic and/or non-small cell lung cancer. Over the next 6-12 months, we will be developing
    and refining these biomarker assays for use in our clinical trials, which should be completed in the 1H&rsquo;22. We anticipate validating
    our approach and confirming our hypothesis in a planned Phase 2B study expected to start in the 2H&rsquo;22 and, depending on the
    results, conducting a Phase 3 pivotal trial in 2023-2024. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS6422
    is an orally administered irreversible enzyme inhibitor administered in combination with capecitabine. On August 2, 2021, we enrolled
    the first patient in our Phase 1B dose-escalation maximum tolerated dose trial in patients with advanced refractory gastrointestinal
    (GI) tract tumors. We anticipate completing an interim cohort analysis in the fourth quarter of 2021 (4Q&rsquo;21); determine the
    maximum tolerated dose (MTD) in the second half of 2022; and, depending on the results, begin a pivotal Phase 2B/3 trial in 2023-2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    only non-clinical asset is PCS11T, an analog of SN38 (SN38 being the active metabolite of irinotecan), and a next generation irinotecan
    drug for multiple types of cancers. PCS11T is presently in the IND pre-clinical toxicology stage. We hope to submit an IND in the
    2H&rsquo;22 or 1H&rsquo;23, followed by a Phase 1B maximum tolerated dose trial. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="f424b5_001.jpg" ALT="" STYLE="height: 264px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Key</U></B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FPI
    &ndash; First Patient In (i.e. randomized)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IND
    &ndash; Investigational New Drug</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MTD
    &ndash; Maximum Tolerated Dose</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPA
    &ndash; FDA Special Protocol Assessment</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form 10-K for the year ended December 31, 2020 and subsequently filed Quarterly Reports on Form 10-Q provide additional
information about our business, operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Delaware corporation and our principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
Our telephone number is (443) 776-3133. Our website is www.processapharmaceuticals.com. The information found on, or otherwise accessible
through, our website is not incorporated into, and does not form a part of, this prospectus supplement or any other report or document
we file with or furnish to the SEC. We have included our website address in this prospectus supplement solely as an inactive textual
reference. Investors should not rely on any such information in deciding whether to purchase our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a more complete description of the terms of the common stock being offered by this prospectus supplement and the accompanying prospectus,
see &ldquo;Description of Securities&rdquo; in the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 28%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock offered by us:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 72%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock having an aggregate offering price of up to $30,000,000.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manner
    of offering:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At-the-market&rdquo;
    offering that may be made from time to time through our Sales Agent, Oppenheimer. See &ldquo;Plan of Distribution&rdquo; beginning
    on page S-9.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds for general corporate purposes, which may include conducting clinical trials, research and development
    activities and working capital, as well as for capital expenditures, investment and acquisitions or licensing transactions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    investment in our common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-5 of this prospectus
    supplement and other information included in this prospectus supplement, the accompanying prospectus and the documents incorporated
    by references in this prospectus supplement and the accompanying prospectus for a discussion of factors you should carefully consider
    before deciding to invest in our common stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
Capital Market symbol:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PCSA&rdquo;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should
consider carefully the specific risk factors discussed in the sections entitled &ldquo;Risk Factors&rdquo; contained in our most recent
Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q which are incorporated
into this prospectus supplement and the accompanying prospectus by reference in their entirety, as updated or superseded by the risks
and uncertainties described under similar headings in the other documents that are filed after the date hereof and incorporated by reference
into this prospectus supplement and the accompanying prospectus, together with other information in this prospectus supplement and the
accompanying prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection
with this offering. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties
not presently known to us, or that we currently view as immaterial, may also impair our business. Past financial performance may not
be a reliable indicator of future performance, and historical trends should not be unduly relied upon to anticipate results or trends
in future periods. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually
occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case,
the trading price of our common stock could decline and you might lose all or part of your investment. Please also read carefully the
section above titled &ldquo;Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management will have broad discretion to use the net proceeds from this offering, and our investment of these proceeds pending any such
use may not yield a favorable return.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion as to the use of the net proceeds from this offering by us and could use them for purposes other
than those contemplated at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard
to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds
are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable, or any, return
for us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investors
in this offering will suffer immediate and substantial dilution in the net tangible book value per share of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares sold in this offering, if any, will be sold from time to time at various prices. However, we expect that the offering price of
our common stock in this offering will be substantially higher than the net tangible book value per share of our outstanding common stock.
Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our
net tangible book value per share after this offering. To the extent outstanding options or warrants are exercised, you may
incur further dilution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
may experience future dilution as a result of future issuances of common stock, including through equity offerings or acquisition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities
in any other offering at a price per share that is less than the price per share paid by investors in this offering. The prices per share
at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions
may be higher or lower than the price per share paid by investors in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
issuances of common stock could further depress the market for our common stock. We expect to continue to incur drug development and
selling, general and administrative costs, and to satisfy our funding requirements, we will need to sell additional equity securities,
which may include sales of significant amounts of common stock to strategic investors, and which common stock may be subject to registration
rights. The sale or the proposed sale of substantial amounts of our common stock or other equity securities in the public markets or
in private transactions may adversely affect the market price of our common stock and our stock price may decline substantially. Also,
new equity securities issued may have greater rights, preferences or privileges than our existing common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we make one or more significant acquisitions in which the consideration includes common stock or other securities, our stockholders&rsquo;
holdings may be significantly diluted. In addition, stockholders&rsquo; holdings may also be diluted if we enter into arrangements with
third parties permitting us to issue shares of common stock in lieu of certain cash payments upon the achievement of milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of shares of our common stock in the public markets could depress the market price of our common stock, which
could impair your ability to sell any shares of common stock that you purchase in this offering at prices above the price you pay in
this offering and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect
that future sales of our common stock would have on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
actual number of shares we will issue in this offering under the Sales Agreement with our Sales Agent, at any one time or in total, is
uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limitations set forth in the Sales Agreement with our Sales Agent and compliance with applicable law, we have the discretion
to deliver placement notices to our Sales Agent at any time throughout the term of the Sales Agreement. The number of shares that are
sold by our Sales Agent after we deliver a placement notice will fluctuate based on the market price of our common stock during the sales
period and the limits we set with our Sales Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
common stock offered hereby will be sold in &ldquo;at-the-market&rdquo; offerings, and investors who buy shares at different times will
likely pay different prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in
their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold,
and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share
sales made at prices lower than the prices they paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be
your sole source of gain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development
and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue and sell shares of our common stock having aggregate sales proceeds of up to $30,000,000 from time to time. Because there is
no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds
to us, if any, are not determinable at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds we will receive from this offering for general corporate purposes, which may include conducting clinical
trials, research and development activities and working capital, as well as for capital expenditures, investments and acquisitions or
licensing transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
management will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant
to this prospectus supplement for any purpose. Pending application of the net proceeds as described above, we may initially invest the
net proceeds in short-term, investment-grade, interest-bearing securities or apply them to the reduction of short-term liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_007"></A><B>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain our future earnings, if any, for use in
our business and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will
be at the discretion of our Board after taking into account various factors, including our financial condition, operating results, current
and anticipated cash needs and plans for expansion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the
public offering price per share of our common stock in this offering and the as adjusted net tangible book value per share of our common
stock immediately after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2021, we had net tangible book value of approximately $21.1 million, or approximately $1.35 per share, based on an aggregate
of 15,604,605 shares of our common stock outstanding as of that date. Historical net tangible book value per share represents
the amount of total tangible assets, less total liabilities, divided by the outstanding number of shares of our common stock. Dilution
in net tangible book value per share to new investors represents the difference between the amount per share paid by purchasers of shares
of our common stock in this offering and the net tangible book value per share of our common stock immediately afterwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
taking into account any other changes in net tangible book value after June 30, 2021, after giving effect to the assumed sale by us of
shares of our common stock in the aggregate amount of $30 million at an assumed public offering price of $5.41 per share, which was the
last reported sale price of our common stock on The Nasdaq Capital Market on August 13, 2021, and after deducting offering commissions
and estimated offering expenses payable by us, our as adjusted net tangible book value at June 30, 2021 would have been approximately
$49.9 million, or $2.36 per share. This represents an immediate increase in net tangible book value of approximately $1.01 per share
to existing stockholders and an immediate dilution in net tangible book value of $3.05 per share to investors in this offering. The following
table illustrates this per share:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    public offering price per share</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.41</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value per share as of June 30, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in net tangible book value per share attributable to new investors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    adjusted net tangible book value per share after this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    per share to new investors purchasing shares in this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding immediately after this offering is based on 15,604,605 shares of common
stock outstanding as of June 30, 2021, and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,627
                                            shares of common stock issuable upon the exercise of vested stock options outstanding as
                                            of June 30, 2021, at a weighted-average exercise price of $17.62 per share, of which
                                            no shares of common stock were subsequently issued upon the exercise of stock options after
                                            June 30, 2021;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,179
    shares of common stock issuable upon the vesting and exercise of stock options outstanding as of June 30, 2021, at a weighted average
    exercise price of $15.74 per share, of which no shares of common stock were subsequently issued upon the exercise of stock options
    after June 30, 2021;</FONT></TD></TR>


<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,551
    shares of common stock issuable for restricted stock units (RSUs) issuable upon meeting distribution restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,250
                                            </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares of common stock
                                            issuable upon the vesting of RSUs;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202,930
    shares of common stock issuable upon the vesting of RSUs granted after June 30, 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">253,725
    shares of common stock issuable upon the exercise of warrants outstanding as of June 30, 2021, at a weighted-average exercise price
    of $11.19 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,107,853
    shares of common stock reserved for future awards under our equity incentive plans as of June 30, 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any of these outstanding options or warrants are exercised at prices per share below the public offering price
per share in this offering or we issue additional shares under our equity incentive plans at prices below the public offering price per
share in this offering, there will be further dilution to new investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient
funds for our current or future operating plans. To the extent that any options or warrants are exercised, new securities are
issued under our equity incentive plans, or we otherwise raise additional capital through the sale of equity or convertible debt securities,
the issuance of these securities could result in further dilution to new investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an equity distribution agreement (the &ldquo;sales agreement&rdquo;) with Oppenheimer &amp; Co. Inc. (the &ldquo;Sales
Agent&rdquo;), under which we may offer and sell up to $30,000,000 of our shares of common stock from time to time through the Sales
Agent. Sales of our shares of common stock, if any, under this prospectus supplement will be made by any method that is deemed to be
an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act or, if expressly authorized by us, in privately
negotiated transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time we wish to issue and sell our shares of common stock under the sales agreement, we will notify our Sales Agent of the number of
shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any
one day and any minimum price below which sales may not be made. Once we have instructed our Sales Agent, unless our Sales Agent declines
to accept the terms of such notice, our Sales Agent has agreed to use its commercially reasonable efforts consistent with its normal
trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of our Sales Agent under the
sales agreement to sell our shares of common stock are subject to a number of conditions that we must meet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
settlement of sales of shares between us and our Sales Agent is generally anticipated to occur on the second trading day following the
date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through
the facilities of The Depository Trust Company or by such other means as we and our Sales Agent may agree upon. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay our Sales Agent a commission of up to 3.0% of the aggregate gross proceeds we receive from each sale of shares of common stock.
Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount,
commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse our Sales Agent for
the fees and disbursements of its counsel, payable upon execution of the sales agreement, in an amount not to exceed $50,000, in addition
to certain ongoing disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding any commissions
or expense reimbursement payable to our Sales Agent under the terms of the sales agreement, will be approximately $285,000. The
remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will report at least quarterly the number of shares of common stock sold through our Sales Agent under the Sales Agreement, the net proceeds
to us and the compensation paid by us to our Sales Agent in connection with the sales of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Sales Agent will provide written confirmation to us before the open on The Nasdaq Capital Market on the day following each day on which
our shares of common stock are sold by our Sales Agent under the sales agreement. Each confirmation will include the number of shares
sold on that day, the aggregate gross proceeds of such sales and the proceeds to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of our shares of common stock on our behalf, our Sales Agent may be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the compensation of our Sales Agent will be deemed to be underwriting commissions or discounts.
We have agreed to indemnify our Sales Agent against certain civil liabilities, including liabilities under the Securities Act. We have
also agreed to contribute to payments our Sales Agent may be required to make in respect of such liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of our shares of common stock pursuant to the sales agreement will terminate upon the earlier of (i) the sale of all shares
of common stock subject to the sales agreement and (ii) the termination of the sales agreement as permitted therein. We and our Sales
Agent may each terminate the sales agreement at any time upon ten trading days&rsquo; prior notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A
copy of the sales agreement is filed as an exhibit to a report filed under the Exchange Act, with the SEC, and is incorporated by reference
into this prospectus supplement and the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oppenheimer
&amp; Co. Inc. and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other
financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its
business, Oppenheimer &amp; Co. Inc. may actively trade our securities for its own accounts or for the accounts of its respective customers,
and, accordingly, Oppenheimer &amp; Co. Inc. may at any time hold long or short positions in such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required by Regulation M, the Sales Agent will not engage in any market making activities involving our common stock while
the offering is ongoing under this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus supplement in electronic format may be made available on a website maintained by our Sales Agent, and our Sales Agent may
distribute the prospectus supplement electronically.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_010"></A><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the common stock offered by this prospectus supplement will be passed upon for us by Foley &amp; Lardner LLP, Jacksonville,
Florida. Our Sales Agent is being represented by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements incorporated in this prospectus supplement by reference from the Company&rsquo;s Annual Report on Form
10-K for the year ended December 31, 2020 have been audited by BD &amp; Company, Inc., an independent registered public accounting firm,
as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements
are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_012"></A><B>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to &ldquo;incorporate by reference&rdquo; the information we file with it, which means that we can disclose important information
to you by referring you to those documents. The information that is incorporated by reference is considered to be part of this prospectus
supplement, and the information that we file later with the SEC will automatically update and supersede this information. We incorporate
by reference any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination
of this offering and the following documents (other than information in documents that is deemed not to be filed, including the portions
of these documents that are furnished under items 2.02 or Item 7.01 of a Current Report on Form 8-K, including any exhibits included
with such Items):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 25, 2021 and amended on April 7, 2021;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Proxy Statement on Schedule 14A for the 2021 Annual Meeting of Stockholders, filed April 22, 2021;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Reports on Form 10-Q for the quarter ended March 31, 2021, filed on May 13, 2021 and for the quarter ended June 30, 2021,
    filed on August 12, 2021;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K filed with the SEC on February 18, 2021, May 26, 2021, June 10, 2021, June 17, 2021 and August
    20, 2021; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock contained in or incorporated into our Registration Statement on Form 8-A, filed September 17, 2020,
    and any amendment or report updating that description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 65.25pt; width: 362.25pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units<BR></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell from time to time up to $75,000,000 of any combination of the securities described in this prospectus, in one or more
classes or series and in amounts, at prices and on terms that we will determine at the times of the offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes the general manner in which our securities may be offered using this prospectus. We will provide specific terms
of the securities, including the offering prices, in one or more supplements to this prospectus. The supplements may also add, update
or change information contained in this prospectus. You should read this prospectus and the prospectus supplement relating to the specific
issue of securities carefully before you invest. This prospectus may be used to offer and sell any of the securities for the account
of persons other than us as provided in an applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer the securities independently or together in any combination for sale directly to purchasers or through underwriters, dealers
or agents to be designated at a future date. The supplements to this prospectus will provide the specific terms of the plan of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the Nasdaq Capital Market under the symbol &ldquo;PCSA.&rdquo; On June 25, 2021, the closing price of our common
stock on the Nasdaq Capital Market was $8.62 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment
in our securities involves a high degree of risk. Before making an investment decision, please read the information in the section titled
&ldquo;Risk Factors&rdquo; on page 5 of this prospectus. Please read carefully and consider these risk factors, as well as those included
in reports we file under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), such as our most recent Annual
Report on Form 10-K, and those included in any applicable prospectus supplement and/or other offering material we file with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 50%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is July 9, 2021.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_001">ABOUT
    THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_002">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_003">PROSPECTUS
    SUMMARY</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_004">RISK
    FACTORS</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_005">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_006">DESCRIPTION
    OF SECURITIES</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_007">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#s_001"><FONT STYLE="font-size: 10pt">LEGAL
    MATTERS</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#s_002"><FONT STYLE="font-size: 10pt">EXPERTS
    </FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#s_003"><FONT STYLE="font-size: 10pt">WHERE
    YOU CAN FIND MORE INFORMATION </FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#s_004"><FONT STYLE="font-size: 10pt">INCORPORATION
    OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B><A NAME="ps_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the SEC using a &ldquo;shelf&rdquo; registration process. Under this
shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to
a total dollar amount of $75,000,000. This prospectus sets forth certain terms of the securities that we may offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides a general description of the securities we may offer. Each time we offer securities, we will, to the extent required
by law, provide a prospectus supplement to this prospectus. The prospectus supplement will contain the specific description of the securities
we are then offering and the terms of the offering. The prospectus supplement will supersede this prospectus to the extent it contains
information that is different from, or that conflicts with, the information contained in this prospectus. For a more complete understanding
of the offering of the securities, you should refer to the registration statement, including its exhibits. You should read this prospectus,
any prospectus supplement and any other offering material together with the documents incorporated herein by reference and the additional
information described herein under the heading &ldquo;Where You Can Find More Information&rdquo; before making an investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained or incorporated by reference in this prospectus and any accompanying prospectus supplement.
We have not authorized anyone else to provide you with different or additional information. We are offering to sell these securities
and seeking offers to buy these securities only in jurisdictions where offers and sales are permitted. This prospectus and any accompanying
supplement to this prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the
registered securities to which they relate.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should not assume that the information contained in this prospectus and any accompanying supplement to this prospectus is accurate on
any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct
on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying supplement
to this prospectus is delivered or securities are sold on a later date.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus may not be used by us to consummate sales of our securities unless it is accompanied by a prospectus supplement. To the extent
there are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document
with the most recent date will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this prospectus, unless the context indicates or otherwise requires, &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Processa Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiary.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ps_002"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and the documents incorporated by reference herein contain certain &ldquo;forward-looking statements&rdquo; within the meaning
of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. All
statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking
statements by words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;seek,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; or the
negative of these words or other comparable terminology. We have based these forward-looking statements on our current expectations and
projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short-
and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks,
uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from
time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances
discussed in this prospectus may not occur, and actual results could differ materially and adversely from those anticipated or implied
in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
Forward-looking statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain funding for our future operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 pandemic on our business, operations or ability to obtain funding;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential market size, opportunity and growth potential for our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize our product candidates,
    if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our pre-clinical studies and clinical trials, and our research and development programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to advance product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to recruit and enroll suitable patients in our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory filings and approvals and other product development
    objectives;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    pricing and reimbursement of our product candidates, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of our product candidates by physicians, patients, third-party payors and others in the medical
    community, if approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model, strategic plans for our business, product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors and our industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements reflect our management&rsquo;s expectations or predictions of future conditions, events or results based on various assumptions
and management&rsquo;s estimates of trends and economic factors in the markets in which we are active, as well as our business plans.
They are not guarantees of future performance. By their nature, forward-looking statements are subject to risks and uncertainties. Our
actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated
in these forward-looking statements. There are a number of factors that could cause actual conditions, events or results to differ materially
from those described in the forward-looking statements contained in this prospectus and the documents incorporated by reference into
this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
an additional discussion under &ldquo;Risk Factors&rdquo; in any applicable prospectus supplement and any related free writing prospectus,
and in our most recent Annual Report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q. These forward-looking statements
are representative only as of the date they are made, and we undertake no obligation to update any forward-looking statement as a result
of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ps_003"></A>PROSPECTUS
SUMMARY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for
patients who have a high unmet medical need condition that effects survival or the patient&rsquo;s quality of life and have few or no
treatment options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to develop drug products that improve the survival and/or quality of life for patients with high unmet medical need conditions.
We are a development company, not a discovery company, that seeks to identify and develop drugs for patients who need better treatment
options than presently exist for their medical condition. In order to increase the probability of development success, our pipeline only
includes drugs which have previously demonstrated some efficacy in the targeted population or a drug with very similar pharmacological
properties has been shown to be effective in the population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
screening criteria for identifying and selecting new candidates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressing
    an unmet or underserved clinical need,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
    demonstrated evidence of efficacy in humans and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">leveraging
    our regulatory science approach to improve the probability for approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have four drugs in various stages of clinical development and one drug in nonclinical development. Our most advanced product
candidate, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX or Trental&reg;).
We have completed a Phase 2A trial for PCS499 in patients with ulcerative and non-ulcerative necrobiosis lipoidica (NL) and in May 2021
enrolled our first patient in our Phase 2B trial for the treatment of ulcerative NL. PCS6422, our second drug, is an orally administered
irreversible enzyme inhibitor administered in combination with capecitabine. We anticipate enrolling the first patient in July 2021 in
our Phase 1B dose-escalation study in patients with Advanced Refractory Gastrointestinal (GI) Tract Tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 17.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCS12852
is a very specific and very potent 5HT4 agonist which has already been evaluated in clinical studies in South Korea for gastric emptying
and GI motility. We are planning on submitting an IND application in the third quarter of 2021 for the treatment of gastroparesis based
on our pre-IND communications with the FDA and plan to begin enrolling patients in the first quarter of 2022. Our fourth clinical
asset, PCS3117, was recently acquired and is a cytosine analog, similar to gemcitabine (Gemzar&reg;) but different enough that some patients
are more likely to respond to PCS3117 than gemcitabine. Potential biomarkers to predict which patients are more likely to respond to
PCS3117 will be developed and evaluated over the next 9-12 months in order to provide a more targeted, precision medicine approach
to treating pancreatic cancer and/or non-small cell lung cancer. Further validation of this approach will be assessed in a Phase
2B study expected to start in the second half of 2022 followed by a Phase 3 registration trial. Our only non-clinical asset is PCS11T,
an analog of SN38 (SN38 being the active metabolite of irinotecan). PCS11T is presently in the IND pre-clinical toxicology stage. We
hope to submit an IND in late 2022 or first half or 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical pipeline (shown below) summarizes each drug, organized by the stage of development. We have enrolled our first patient in our
PCS499 Phase 2B study and expect to enroll our first patient in our PCS6422 Phase 1B PCS6422 study in July 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="table_1.jpg" ALT="" STYLE="height: 441px; width: 670px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form 10-K for the year ended December 31, 2020 and subsequently filed Quarterly Reports on Form 10-Q provide additional
information about our business, operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Delaware corporation and our principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
Our telephone number is (443) 776-3133. Our website is www.processapharmaceuticals.com. The information found on, or otherwise accessible
through, our website is not incorporated into, and does not form a part of, this prospectus or any other report or document we file with
or furnish to the SEC. We have included our website address in this prospectus solely as an inactive textual reference. Investors should
not rely on any such information in deciding whether to purchase our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ps_004"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our common stock involves a high degree of risk. You should carefully consider the specific risks set forth under the caption &ldquo;Risk
Factors&rdquo; in our most recent Annual Report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q, incorporated
into this prospectus by reference, as updated by any future filings we make under the Exchange Act. You should consider carefully those
risk factors together with all of the other information included and incorporated by reference in this prospectus before investing in
any shares of common stock offered by this prospectus. For more information, see &ldquo;Where You Can Find More Information.&rdquo; These
risks are not the only ones faced by us. Additional risks not known, or that are deemed immaterial could also materially and adversely
affect our financial condition, results of operations, our drug candidates, business and prospects. Any of these risks might cause you
to lose all or part of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="ps_005"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we indicate otherwise in the applicable prospectus supplement, the net proceeds from the sale of the securities will be used for general
corporate purposes, which may include conducting clinical trials, research and development activities, working capital, capital expenditures,
investments and acquisitions or licensing transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not determined the amounts we plan to spend on any of the areas listed above or the timing of these expenditures. As a result, our
management will have broad discretion to allocate the net proceeds, if any, we receive in connection with securities offered pursuant
to this prospectus for any purpose. Pending application of the net proceeds as described above, we may initially invest the net proceeds
in short-term, investment-grade, interest-bearing securities or apply them to the reduction of short-term liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ps_006"></A>DESCRIPTION
OF SECURITIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and restated
bylaws. Reference is made to the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, the
Certificate of Incorporation and Bylaws, forms of which are filed with the SEC as exhibits to the registration statement of which this
prospectus is a part, and applicable law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
directly or through one or more underwriters, dealers and agents designated from time to time, or directly to purchasers, or through
a combination of these methods, may offer, issue and sell, together or separately, in one or more offerings, the following securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of our common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of our preferred stock, in one or more series;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
    to purchase shares of our common stock or preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">units
    consisting of any combination of the securities listed above, each on terms to be determined at the time of sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock may also be exchangeable for and/or convertible into shares of common stock, another series of preferred stock, or other
securities. The common stock, preferred stock, warrants, and units are collectively referred to in this prospectus as the &ldquo;securities.&rdquo;
When a particular series of securities is offered, a supplement to this prospectus will be delivered with this prospectus, which will
set forth the terms of the offering and sale of the offered securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the authority to issue an aggregate of 30,000,000 shares of $0.0001 par value common stock and 1,000,000 shares of $0.0001 par value
preferred stock. As of June 25, 2021, there were 15,566,305 shares of common stock outstanding and no shares of preferred stock
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I>. </B>Subject to the rights of holders of preferred stock of any series that may be issued and outstanding from time to time,
holders of our common stock are entitled to receive such dividends and other distributions as may be declared by our Board of Directors
from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I>. </B>Each outstanding share of our common stock is entitled to one vote on all matters submitted to a vote of stockholders
generally. In the event we issue one or more series of preferred or other securities in the future such preferred stock or other securities
may be given rights to vote, either together with the common stock or as a separate class on one or more types of matters. The holders
of our common stock do not have cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I>. </B>In the event of any liquidation, dissolution or winding up of the Company, the holders of our common stock will be entitled,
subject to any preferential or other rights of any then outstanding preferred stock, to receive all assets of the Company available for
distribution to stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preemptive
Rights</I>. </B>As of the date hereof, the holders of our common stock have no preemptive rights in their capacities as such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors</I>. </B>Holders of common stock do not have cumulative voting rights with respect to the election of directors. At any
meeting to elect directors by holders of our common stock, the presence, in person or by proxy, of the holders of a majority of the voting
power of shares of our capital stock then outstanding will constitute a quorum for such election. Directors may be elected by a plurality
of the votes of the shares present and entitled to vote on the election of directors, except for directors whom the holders of any then
outstanding preferred stock have the right to elect, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is authorized, subject to certain limitations prescribed by law, without further stockholder approval, to issue from time to time
up to an aggregate of 1,000,000 shares of preferred stock in one or more series and to fix or alter the designations, preferences, rights
and any qualifications, limitations or restrictions of the shares of each such series thereof, including the dividend rights, dividend
rates, conversion rights, voting rights and terms of redemption of shares constituting any series or designations of such series. The
rights of holders of our common stock may be subject to, and adversely affected by, the rights of the holders of any preferred stock
that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of
control and may adversely affect the voting and other rights of holders of our common stock. As of the date of this prospectus, there
were no shares of preferred stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, we granted 336,860 restricted stock awards to our employees and directors. On August 5, 2020, we issued
324,360 restricted stock awards under the 2019 Omnibus Incentive Plan to our employees and directors, of which 214,078 shares of common
stock vested on October 6, 2020 when we successfully completed our underwritten public offering and up-listed to the Nasdaq Capital Market.
The remaining 110,282 shares of common stock vest on the first and second year anniversaries of the grant date. Certain employees
forfeited 23,804 shares to pay for federal, state and local income taxes, leaving 319,306 restricted stock awards outstanding. In the
fourth quarter of 2020, we issued 12,500 restricted stock awards to our Chief Operating Officer upon hire which vest one year from their
hiring date. We valued the restricted stock awards based on the closing shares price on the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2021, we had 122,782 shares of unvested restricted stock that was granted in 2020 outstanding. During the three months ended
March 31, 2021, we issued 12,500 restricted stock units (RSUs) and 100,000 warrants to a consultant for services to be provided
in 2021. We valued the RSUs based on the closing share price on the date of grant. The fair value of the warrants granted was estimated
using the Black-Scholes option pricing model at the date of grant. During the three months ended March 31, 2021, we also agreed to grant
64,556 RSUs to our employees and a consultant in accordance with our employment/consulting agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2019, we granted stock options for the purchase of 129,919 shares of our common stock to employees and directors. The stock options awarded
contained either service or performance vesting conditions, have a contractual term of five years and an exercise price of $16.80. At
March 31, 2021, we had outstanding options to purchase 152,806 shares of our common stock of which options for the purchase of 115,750
shares of our common stock were vested. All the options outstanding have exercise prices higher than the closing market price at March
31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2021, we granted 30,000 stock options to a consultant in accordance with a consulting
agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants, in one or more series, for the purchase of our common stock or preferred stock. Warrants may be issued independently
or together with our common stock or preferred stock and may be attached to or separate from any offered securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus supplement accompanying this prospectus relating to a particular series of warrants will describe the terms of those warrants,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title and the aggregate number of warrants,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    security for which each warrant is exercisable,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates on which the right to exercise such warrants commence and expire,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which such warrants are exercisable,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    periods during which and places at which such warrants are exercisable,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms of any mandatory or optional call provisions,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices, if any, at which the warrants may be redeemed at the option of the holder or will be redeemed upon expiration,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    identity of the warrant agent, and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exchanges, if any, on which such warrants may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the particular terms of the documents pursuant to which the warrants will be issued, which will be described in more detail
in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have outstanding warrants to purchase shares of our common stock to various persons and entities,
under which we could be obligated to issue up to 530,268 shares of common stock, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">276,543
    shares of common stock issuable upon the exercise of outstanding warrants allowing the holders to purchase shares of common stock.
    The exercise price for 275,828 shares is $19.07 per share and for 715 shares is $17.16. These warrants expire between June 29, 2021
    and July 29, 2021. Warrants for 18,819 shares of common stock contain cashless exercise provisions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,107
    shares of common stock issuable upon the exercise of outstanding warrants allowing the holders to purchase shares of common stock
    at an exercise price of $17.16 per share expiring on July 2, 2022.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,350
    shares of common stock issuable upon the exercise of outstanding warrants allowing the holders to purchase shares of common stock
    at an exercise price of $19.04 per share through December 19, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000
    shares of common stock issuable upon the exercise of outstanding warrants allowing the holders to purchase shares of common stock
    at an exercise price of $7.18 per share through January 11, 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79,268
    shares of common stock upon exercise of outstanding warrants allowing the holders to purchase shares of common stock at an exercise
    price of $9.30 per share through February 16, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units consisting of one or more warrants, shares of preferred stock, shares of common stock or any combination of such securities.
The applicable prospectus supplement will describe the terms of the units and of the securities comprising the units, including whether
and under what circumstances the securities comprising the units may be traded separately. You should read the particular terms of the
documents pursuant to which the units will be issued, which will be described in more detail in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation provides that, to the fullest extent permitted by the Delaware General Corporate Law
(&ldquo;DGCL&rdquo;) as it may hereafter be amended, none of our directors will be personally liable to us or our stockholders for monetary
damages for breach of fiduciary duty as a director. Under the DGCL as it now reads, such limitation of liability is not permitted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any breach of the director&rsquo;s duty of loyalty to us or our stockholders;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    payments of unlawful dividends or unlawful stock purchases or redemptions under Section 174 of the DGCL; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any transaction from which the director derived an improper personal benefit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions will have no effect on the availability of equitable remedies such as an injunction or rescission based on a director&rsquo;s
breach of his or her duty of care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation and our amended and restated bylaws include provisions that require us to indemnify
and advance expenses, to the fullest extent allowable under the DGCL as it now exists or may hereafter be amended, to our directors or
officers for actions taken as a director or officer of us, or for serving at our request as a director or officer at another corporation
or enterprise, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the DGCL provides that a corporation may indemnify directors and officers, as well as other employees and individuals, against
expenses, including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement, that are incurred in connection with various
actions, suits or proceedings, whether civil, criminal, administrative or investigative, other than an action by or in the right of the
corporation, known as a derivative action, if they acted in good faith and in a manner they reasonably believed to be in or not opposed
to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to
believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only
extends to expenses, including attorneys&rsquo; fees, incurred in connection with the defense or settlement of such actions, and the
statute requires court approval before there can be any indemnification if the person seeking indemnification has been found liable to
the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation&rsquo;s
bylaws, disinterested director vote, stockholder vote, agreement or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws require us to indemnify any person who was or is a party or is threatened to be made a party to, or was otherwise
involved in, a legal proceeding by reason of the fact that he or she is or was a director or officer of the Company or is or was serving
at our request as a director or officer of another corporation or enterprise, as the case may be, to the fullest extent authorized by
the DGCL as it now exists or may hereafter be amended, against all expense, liability and loss (including attorneys&rsquo; fees, judgments,
fines, Employee Retirement Income Security Act excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered
by such director or officer in connection with such service. The right to indemnification in our amended and restated bylaws includes
the right to be paid by the Company the expenses incurred in defending any proceeding for which indemnification may be sought in advance
of the final disposition of such proceeding, subject to certain limitations. We carry directors&rsquo; and officers&rsquo; insurance
protecting us, any director, officer, employee or agent of ours or who was serving at the request of the Company as a director, officer,
employee or agent of another corporation or enterprise, as the case may be, against any expense, liability or loss, whether or not we
would have the power to indemnify the person under the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability and indemnification and advancement provisions in our amended and restated certificate of incorporation and our
amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of fiduciary duty. These
provisions also may reduce the likelihood of derivative litigation against our directors and officers, even though such an action, if
successful, might otherwise benefit us and our stockholders. In addition, your investment in our common stock may be adversely affected
to the extent we pay the costs of settlement and damage awards under these indemnification provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Anti-Takeover Effects</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
of Delaware Law</I>. </B>We are a Delaware corporation and Section 203 of the DGCL applies to us. It is an anti-takeover statute that
is designed to protect stockholders against coercive, unfair or inadequate tender offers and other abusive tactics and to encourage any
person contemplating a business combination with us to negotiate with our Board of Directors for the fair and equitable treatment of
all stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 203 of the DGCL, a Delaware corporation is not permitted to engage in a &ldquo;business combination&rdquo; with an &ldquo;interested
stockholder&rdquo; for a period of three years following the date that the stockholder became an interested stockholder. As defined for
this purpose, the term &ldquo;business combination&rdquo; includes a merger, consolidation, asset sale or other transaction resulting
in a financial benefit to the interested stockholder. The term &ldquo;interested stockholder&rdquo; is defined to mean a person who,
together with affiliates and associates, owns, or within three years did own, 15% or more of the corporation&rsquo;s outstanding voting
stock. This prohibition does not apply if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to the time that the stockholder became an interested stockholder, the Board of Directors of the corporation approved either the
    business combination or the transaction resulting in the stockholder becoming an interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction resulting in the stockholder becoming an interested stockholder, the stockholder owns at least 85%
    of the outstanding voting stock of the corporation, excluding voting stock owned by directors who are also officers and by certain
    employee stock plans; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    or subsequent to the time that the stockholder became an interested stockholder, the business combination is approved by the Board
    and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds
    of the outstanding voting stock that the interested stockholder does not own.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Delaware corporation may elect not to be governed by these restrictions. We have not opted out of Section 203.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
Notice Procedures</I>. </B>Our bylaws establish an advance notice procedure for stockholder nominations of persons for election to our
Board of Directors and for any proposals to be presented by stockholders at an annual meeting. Stockholders at an annual meeting will
only be able to consider nominations and other proposals specified in the notice of meeting or brought before the meeting by or at the
direction of our Board of Directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled
to vote at the meeting and who has given our corporate secretary timely written notice, in proper form, of the stockholder&rsquo;s intention
to nominate a person for election as a director or to bring a proposal for action at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &ldquo;PCSA.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
transfer agent is Equiniti Trust Company, 3200 Cherry Creek Dr. South Suite 430 Denver, CO 80209; telephone (303) 282-4800.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ps_007"></A>Plan
of distribution</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities on a delayed or continuous basis through one or more agents, underwriters or dealers, directly to one or more
purchasers, through a combination of any of these methods of sale, in negotiated transactions (including block trades), in transactions
that are deemed to be &ldquo;at the market&rdquo; offerings as defined in Rule 415 of the Securities Act or in any other manner, as provided
in the applicable prospectus supplement. We will identify the specific plan of distribution, including any underwriters, dealers, agents
or direct purchasers and their compensation in a prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may distribute the securities from time to time in one or more transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    a fixed price or prices, which may be changed;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    market prices prevailing at the time of sale;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    prices related to prevailing market prices; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
    negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities, underwriters may be deemed to have received compensation from us in the form of underwriting
discounts or commissions and may also receive commissions from purchasers of the securities for whom they may act as agent. Underwriters
may sell the securities to or through dealers, and dealers may receive compensation in the form of discounts, concessions or commissions
from the underwriters and/or commissions from the purchasers for whom they may act as agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we use an underwriter in the sale of the securities being offered by this prospectus, we will execute an underwriting agreement with
the underwriter at the time of sale and we will provide the name of any underwriter in the applicable prospectus supplement. We will
describe in the applicable prospectus supplement any underwriting compensation we pay to underwriters or agents in connection with the
offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers. Dealers and
agents participating in the distribution of the securities may be deemed to be underwriters, and any discounts and commissions received
by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may
enter into agreements with any underwriters, dealers and agents which may entitle them to indemnification against and contribution toward
certain civil liabilities, including liabilities under the Securities Act, and to reimbursement for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we specify otherwise in the related prospectus supplement, each series of securities offered will be a new issue with no established
trading market. We may elect to list any series of securities on any exchange, but we are not obligated to do so. It is possible that
one or more underwriters or agents may make a market in a series of offered securities, but will not be obligated to do so and may discontinue
any market making at any time without notice. Therefore, we cannot assure you as to the liquidity of the trading market for the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
indicated in the applicable prospectus supplement, we may authorize underwriters, dealers or other persons acting as our agents to solicit
offers by certain institutions or other suitable persons to purchase the securities from us at the public offering price set forth in
the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on the date or dates stated in the
prospectus supplement. We may make delayed delivery with various institutions, including commercial and savings banks, insurance companies,
pension funds, investment companies and educational and charitable institutions. Delayed delivery contracts will be subject to the condition
that the purchase of the securities covered by the delayed delivery contracts will not at the time of delivery be prohibited under the
laws of any jurisdiction in the United States to which the purchaser is subject. The underwriters and agents will not have any responsibility
with respect to the validity or performance of these contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
facilitate an offering of a series of the securities, certain persons participating in the offering may engage in transactions that stabilize,
maintain, or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involves
the sale by persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would
cover the over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In
addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market
or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities
sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain
the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be
discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="s_001"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus will be passed upon for us by Foley &amp; Lardner LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><A NAME="s_002"></A>EXPERTS<FONT STYLE="font-weight: normal">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company as of December 31, 2020 and 2019 and for the years ended December 31, 2020 and 2019
appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, have been audited by BD &amp; Company, Inc.,
an independent registered public accounting firm, as set forth in their report thereon and incorporated herein by reference. Such consolidated
financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts
in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="s_003"></A>WHERE
YOU CAN FIND MORE INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other information with the SEC. We also filed a registration statement
on Form S-3, including exhibits, under the Securities Act with respect to the securities offered by this prospectus. This prospectus
is a part of the registration statement, but does not contain all of the information included in the registration statement or the exhibits.
The SEC maintains a web site, <I>www.sec.gov</I>, that contains reports, proxy and information statements and other information regarding
issuers that file electronically with the SEC. You may review the registration statement and any other document we file on the SEC&rsquo;s
web site. Our SEC filings are also available to the public on our website, <I>www.processapharmaceuticals.com. </I>The information on
our website, however, is not, and should not be deemed to be, a part of this prospectus.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="s_004"></A>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are &ldquo;incorporating by reference&rdquo; specified documents that we file with the SEC, which means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporated
                                            documents are considered part of this prospectus&#894;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            are disclosing important information to you by referring you to those documents&#894; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            we file with the SEC will automatically update and supersede information contained in this
                                            prospectus.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference the documents listed below and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d)
of the Exchange Act after the date we filed the registration statement of which this prospectus is a part and before the effective date
of the registration statement and any future filings we will make with the SEC under those sections, except to the extent that any information
in such filing is deemed &ldquo;furnished&rdquo; in accordance with rules of the SEC:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC
                                            on March 25, 2021 and amended on April 7, 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Proxy Statement on Schedule 14A for the 2021 Annual Meeting of Stockholders, filed with the
                                            SEC on April 22, 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on
                                            May 13, 2021;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Current Reports on Form 8-K filed with the SEC on February 18, 2021 (excluding Item 7.01
                                            and the exhibit related thereto), May 26, 2021, June 10, 2021 and June 17, 2021; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            description of our common stock contained in or incorporated into our Registration Statement
                                            on Form 8-A, filed September 17, 2020, and any amendment or report updating that description.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, documents or portions thereof containing information furnished under Items 2.02 and 7.01 of any Current Report on Form
8-K, including the related exhibits under Item 9.01, are not incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Any
statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or
any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the
statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request a copy of any of these filings, at no cost, by request directed to us at the following address or telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7380
Coca Cola Drive, Suite 106</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hanover,
Maryland 21076</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(443)
776-3133<BR>
Attention: Wendy Guy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not assume that the information in this prospectus or any prospectus supplement, as well as the information we file or previously
filed with the SEC that we incorporate by reference in this prospectus or any prospectus supplement, is accurate as of any date other
than the respective date of such documents. Our business, financial condition, results of operations and prospects may have changed since
that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>$30,000,000</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_003.jpg" ALT="" STYLE="height: 58px; width: 340px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>Oppenheimer&nbsp;&amp; Co.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>August
20, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Options: NewSection Last; Value: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 >,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HI
M#0#0%Q:*1C@9JG?ZG;:;:/=7D\4,*<EW; Q_C[4 E=V1;;..*;NQ7C?B;XX(
MF^#P[:"7M]IN!A?JJYY^IK@5\0^._%=UBUO-2NCG@6RX13^''\ZAS1TQPTFK
MRT/J+S!QR*<K$D=*\0M;WQAX;T^"]U:22.X5QNB=]XDCZ<^AKV+3+U=0TZVO
M(_N3H)!^(HA-2T"MAW32E>Z9?HIH/-.JSF"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXE;:%3]QA@<2?-P>.V:Q=2L/$>K_  =31+32[RQU&S2*&6*0JIG51\P0@\T
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MW;2Q3  0-&< DOGK@'COP*9<_P!O2?%V'Q2OA75C80P?9R-J;C\I&X?-TR:
M)KN;_A*?CHFCWX\S3-*@,B6S?<:3:#N(Z'EJ[?7/!.FZYJ^D:F[S6]SIL@>-
MH"%WC^Z>.GTQ7)>(] U?1O'UKXXT6PDOHGBV7ME&1YH!4#*C/)X''K70R^)=
M4UQ4L]"TC4[*61QYUUJ%J8D@4$;A@_>;'''K0!4U>R\/^'?&#^+-7OY9;RXC
M$-I9E?,*'@'RU SDX_G7)17DTWQXTFY72Y]*^U6C;XY-H>9?FPSA>G0<&K%Q
M9ZYHOQBN]>O-!O=7L9XS':26P5_)!QSR0!W!] 33-:M_%4'Q&TGQ;=>'9)8$
MB:(6MBXEDB^]M\P\ 'YLDC@#UH L_&8?\3OP9[ZACK_M(*O_ !*DU31M>T3Q
M5::<-2L-/619[<$_*6_C'7D#OCBL3Q]!XH\0W?AUQX9O&N-,F\^Y:(+Y;,=I
MPGS$G&.]=9?:_P"(8/$6GW\.BZD^D/8O]KM1&#)$^\ $ '!;V!/&30!7\ ZA
MX8\0>(M1U_0I3!<W%O&EW8-'M*,"2)./7ID>GO7HU>8>&M%6[^)TOB33-(N-
M+TP6AAD\Z$PFXF;!+!.PX'7'(KT^@ HHHH #TI*4\T8H :1Q7 _%#PY'XBT2
M%'9H_(<NLJKNV'&.1Z=OQKO\4UHU92",@C!![BJC+E=R9)M:,XOPU>V&A^&K
M'2X%+_9H0NX 89NI/7N<YKB++PFB:^=:UC48[F;SC.8BOR[L\9)ZXX_*O3KW
MPGI$T<D@LPLFTX,9*\_0<5A:!H]A;12IJ3B[G$S,"RD%%[ BK=>C#61S3A6E
MI<>VM27K&.$23DGA47Y:MVVA7=X0UZ_E1?\ /->I^M;,=U86\>V"/:!V5<56
MGUI"=J,%/IU)KFK9I2@O<%#"7=ZCN7HHK73+?RXHU10/NCJ:K([W]SA<[%^\
M?Z5!!;75\VZ0-#'ZGJU;-O;1VZ!(UP!^M<*=3$23>QW12@K(E48X'04X@$8H
MQ2UZ*5E9$C=@QCFEVC.??-+13 3:/>C:,Y[TM% #=@]^N:3RQZG\Z?10 W8*
M-@]33J* &")5  S@=*78/>G44 ,,2GN?2CRESWXZ>U/HH 9Y8R2<G/O1Y8SG
M)SC&:?10 P1*/7\Z7RUIU% #2@.??O@4! .YIU% #?+4G-&P8QDTZB@!OEKZ
M4!!ZG-.HH :(U&.^.F:/+&<\YY_6G44 -V#ODGUHV#.>_K3J* &[!Z4! *=1
M0 P1*,]>:/+7.?XNF>]/HH :(P/7GK[T;!NSDTZB@!AC5NOK2^6I.3G/Y4ZB
M@!NP>])Y8P1DX-/HH 8(U'KZ]:78/4TZB@!NP>IH**3DTZB@!NP<=>*/+'!Y
MS3J* &A /7\Z"@)SWIU% #?+7KCGUI!& <Y/TS3Z* &A!G)Y/J:=110 4444
M %%%% !1110 C#(JA=:5:W9#2H=X& P.#11655)Z,"K_ ,([:9^9IF'H9.*N
M6^FVEM_JH%4^N,G]:**RC0IQ=TA%S ]*7O1171$8O>BBBF@"BBBF 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>f424b5_001.jpg
<TEXT>
begin 644 f424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $< M(# 2(  A$! Q$!_\0
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M)8%-74AO&-:.)ZY_PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
M%5Y'13^H?WOP%]=_NGKG_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_
M /%5Y'11]0_O?@'UW^Z>N?\ "=^#_P#H:]#_ /!C#_\ %5')\0?!L3PHWBK1
MB97V+MO8V .TM\Q!PHPIY.!G ZD ^3UGZC_Q_:1_U]M_Z(EI/ V5^;\!K&7?
MPGMG_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5Y'13^H?WOP%]
M=_NGKG_"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 57B*Z]IS7
M#PF:1&1_+8R0.BJW8%BH&3VYYJZEQ%)/)"K9DB +C!XSTI+!)[2*>,:WB>P_
M\)WX/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,57D=%/ZA_>_ GZ[_=/
M7/\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ\CJA=ZS96,PBG
M:<,6"C9;R."QZ#*J1GVI/ I;R&L8WM$]K_X3OP?_ -#7H?\ X,8?_BJ/^$[\
M'_\ 0UZ'_P"#&'_XJO'X)TN85ECW;&Z;D*G\00"/QJ2G]0_O?@+Z[_=/7/\
MA._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ\CI,C=MR,]<4?4/[W
MX!]=_NGKO_"=^#_^AKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%5Y'11]0_
MO?@'UW^Z>L0?$'P;<V\4Z>*M&"2('427L:, 1GE6(*GV(!'>I/\ A._!_P#T
M->A_^#&'_P"*KQ/0?^1=TS_KTB_] %%WK5A8W/V>YDD239OX@=@%[G<!C [G
M/%3]25DW(KZV[M*)[9_PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
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M!\H-#P*6KE^ +&-Z*)[-_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\
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MX_\ 0X:T*2P-_M?@#QEOLGKG_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\
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MXIT\5:,$D0.HDO8T8 C/*L05/L0".]>3UGZ#_P B[IG_ %Z1?^@"CZCK;F_
M/KFE^4]L_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*KR.BG]0
M_O?@+Z[_ '3US_A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*KR.BC
MZA_>_ /KO]T]<_X3OP?_ -#7H?\ X,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJO(Z
MBN;F*SMGN)BPC098JA8@?0 FD\"DKN7X#6-OHHGL/_"=^#_^AKT/_P &,/\
M\51_PG?@_P#Z&O0__!C#_P#%5X@/$.F&VDN/M#B.(*7W0N& ;H=I&<'UQBM,
M'(R*%@4]I \8UO$]<_X3OP?_ -#7H?\ X,8?_BJ/^$[\'_\ 0UZ'_P"#&'_X
MJO(Z*?U#^]^ OKO]T]<_X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_
M (JO&[R^M["-)+EV1'<("$9N3TS@''XTRZU*ULKBW@N)"CW#;(LHQ#-Z;@,
M_4TOJ*_F']<?\I[/_P )WX/_ .AKT/\ \&,/_P 51_PG?@__ *&O0_\ P8P_
M_%5XS+J%K#>Q6;R'[1*I945&;@=2<# 'UIMOJMG=7"00REI'B\Y1L893.,Y(
MQUH^I+;F']<>_*>T?\)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5>1T@()(!!QP?:G]0_O?@3]=_NGKO_  G?@_\ Z&O0_P#P8P__ !5'_"=^
M#_\ H:]#_P#!C#_\57D=%'U#^]^ ?7?[IZY_PG?@_P#Z&O0__!C#_P#%4?\
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M,#UYIZPW[Z!<3+)J0N8[A@J,T@8H),@@'D_+_A7>?\(WXK_Z%6__ / FT_\
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M@;22V>@YY]:;H+(]@SI97%IOE=V2XCV,6)R3CTYX^E='_P (WXK_ .A5O_\
MP)M/_CU'_"-^*_\ H5;_ /\  FT_^/5?MZ5[\Q#HU;6Y2A6?-_R,5E_UZ7'_
M *'#6_\ \(WXK_Z%6_\ _ FT_P#CU9D^@>)AXFL8CX:O1,UG<LL?VBVRRAX-
MQSYN."5ZG/S#&><$L12_F"-"I_*.D<1Q,Y#$*"2%4L?P Y-<=9:7GPU/<RI>
MO=I;S0QPR0E2FXGA5V@G.1SS7H7_  C?BO\ Z%6__P# FT_^/4?\(WXK_P"A
M5O\ _P ";3_X]43J49[RZ6*A3JQVB<'9RWBV=Y"T6I%,VXC 21& *J'P2,@
MYR!T[8ZU+9#4?LU@UP+YI8YF0QDNN1O.&8]\*/XL@COFNW_X1OQ7_P!"K?\
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M %%%% !17'0^,S:^+]0TG4T$=F+A8K:[Z*KE%;8_IG/!_"NQIM"3N%<_>?\
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MPF$UK.N^.0*1D?0@$?0\UAZ3XK:[U?Q!97T A73MD\)C5G:6V9,A\#))RK\
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MB/\ Z&6Y_P# 6#_XBI**/[>S'_GY^"_R#ZCA_P"7\7_F1_:_$?\ T,MS_P"
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M_P"(J2BC^WLQ_P"?GX+_ "#ZCA_Y?Q?^9']K\1_]#+<_^ L'_P 11]K\1_\
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MS1_PF6E_\^NN?^"*]_\ C- '045S_P#PF6E_\^NN?^"*]_\ C-'_  F6E_\
M/KKG_@BO?_C- &OJ%M!>:=<V]U!'/!)&RO'*@96&.A!X->5?#GP[93_#@75Y
MX<T= ]@XCNHT5Y;@$ON$N4'HO&6'?/IW-UXHT.]M9+:[T[6)[>5=LD4OA^\=
M''H08<$53AU+PE;:9+ID'AZ]BL)23):Q^&;I8GSUR@@P>@[=J35U)=U_F-/;
MR9YO8^$I$^$^H:S<6UA!93>'5"6EO\XFE4;A<2910).W&3_M&NV\6:981_ ^
M[MTL;988M,$L<8B4*C[0=P&, Y).?4UH_P!H>$/[*_LK_A'+S^SMV[[)_P (
MQ=>3G.<[/(QG//2E?4O"4NE)I4GAZ]?3D.5M&\,W1B4YSPGD8'//2KD[W\VB
M8Z-/L<;JGA:XT;PK/=W$5C;1W6J:=+:V%H2\-J1(BEE)5<,V23A1U[]:U[_X
MB:I;>%GOXVTM+^&:]5H9(W/GK;L02BAAMR!R2QQD<-G%;DVJ^%+G3X=/GT"^
MELH"#%;2>&;MHXR.FU3!@8]JBCN_!D41BC\,W21DNQ1?"]T!EAACCR.X !]:
M3>XUI82X\8:A:37=U/#;FQ73VNK:".-FDF98U=AY@; (SC85!Q@@GD#1\+:[
MJ&J:!+J&NVT5B@'FI+YB*CPE0P<[9'VXR1DMSC/&<"&/7O#<,PFBT;4TE$?E
M!U\.78;9_=SY/3VZ4MMX@\.65D;*UTC5(+0YS!%X<O%3GK\HAQSWH?4%TN5O
M!=G/IFN>([22.W,4L\=Y#-:*4A99%(P$R0K?)DD$YW9[UEV%N]EXG\B_L+'4
MK#5[F=8=2MV_>M\KDPW*'[ZJ-Z@\@8 P*WK'Q%X>TNU6UT_2=4M+=22L5OX=
MO(T&>N (0*B;6/"SSS3MH6H&:>+R99#X:N]TD?\ <8^3ROL>*3_2P?U_7]?Y
MG(?##P[+:0V?B)4L=.T^&"YBD%LQWWG[UL-*-J@; "!RQYZCI6WX3OKZR\>Z
MO8ZG:7=FNK1K?VR7<D;%G0!)0NQV&,;" <'':M"'4/"%OILVFP>'+R*PF.Z6
MU3PQ=+$YXY9!!@]!U':E.I>$FOK>^;P]>F[MU"03GPS=>9$HZ!6\C*@9/ IW
MU_#^OF)[/^OZT*_C#3M#E\4Z!>W>L)8:M#<*UN7O-A:('YHTC+88N2HX!)S[
M8K&TG[;-XM2296CENK[4K>]E7Y'^SIM\K)'.%^7:>VXXZUT-SJ?A*]U&/4;K
MP]>SWT6/+N9?#-TTB8.1AC!D8/2IGUWPU)-<S2:+J3RW4?E7#MX;NRTR?W7/
MD_,.3P:2T7W_ (_UJ4]?P.<T+1]"?POKFC:#K6F7-O?W3_8[>YF^UQ1$I]PC
M?EB=KOC.1D$CBNQ\&/(_@S2?.B>*1+98V5Y#(<K\N=QY.<9S[UBQS^"8K,V<
M?A:X2U,@E,*^%;D(7'1MOD8R/7K6L/&.E* !::X . !H-[Q_Y!IW_3\"?^#^
M)T-%<_\ \)EI?_/KKG_@BO?_ (S1_P )EI?_ #ZZY_X(KW_XS2&=!17/_P#"
M9:7_ ,^NN?\ @BO?_C-'_"9:7_SZZY_X(KW_ .,T =!7/^!/^2>>&O\ L%6O
M_HI:/^$RTO\ Y]=<_P#!%>__ !FCP)_R3SPU_P!@JU_]%+0!T%%%% !7/V?_
M "4/6?\ L%6'_HV[KH*Y^S_Y*'K/_8*L/_1MW0!T%%%% !17$^)O'5_X<UB[
MM?[&MKBTM;$Z@\WV\HYB#!6 3RB-V3P-V#ZCI6DOBF34-4_L_1;!;J6*&*>Z
M:XF,"P+("57A6)? SMP!ZD4+75 ]#I**YJ7Q7(-:72XM/7[4MO\ :)+>:Y$<
MQ7+ >4F")#E>>0!D<G-3V_B&=_%]_H4UBB);VB7<<\<Q<R*S%<%-HVG*GH3V
MH WJ*X8_$.XMK+6Y-2\/7%A<Z;+"@BFN%9'25L([2*"$'=NNT>M.O_'=[!IM
M@UEHEO=ZI=W$D"V;:I% K",D,\<C@>8N<8PH.#T&*$K_ -=P.WHKF;OQ3>6/
MBO3=(GT*X%G?9C74%F4J)@A<IL^]C /S''TKIJ.EP"N?\0_\ASPG_P!A63_T
MBNJZ"N?\0_\ (<\)_P#85D_](KJ@#H**** ,>Z\0Q1:H^G6EC>:A<0A6N!:A
M,6ZMG!8NR@]"=JY;';D5I6MREW;1W$8<(XR ZE6_$'D?0UR#Z5J^B:UK\]A;
M75S#K+I*D]H\ EM9 @0[A,0I7Y01C=U(VU@>)O"_BW4]'T^":"/4]5M[42MJ
M)EB1H[D2HVV-<(JC:&PP7/8D<Y:UM\OZ^0/J>H7%Q#:6TMQ<2+'#$I=W8X"J
M.233U8,H8=",BO-/$/@^_O[;Q/'9Z/&TFHVI(EF:+?)+N&U%<')7"Y^?[I("
MG&<7-'\)M%XNU:Z_L,6%JUK:_89E\H+'-'&RG"HQ((#@<C! /;&5TO\ UL']
M?D>@45X?JGAC4]*\)W$FHV*PHG]GQ.C&-OM5TMP/,N!M)Y8,!N;#'N!BMB^\
M'ZS<^'[K3HM @^RW=[=306LDT8^PHT.(\(&*9,G/&[;G(P>0VK7_ *_K^KCM
MJD>L45YUI?A?4)O%-E=:OI3E%T2VAENFEC.+J-]_.U]Q(..<$5G:7X%U&+PW
M>Q:I:WMY?RS!IHG>U>&X="Q60)@!PV0#YIW=.?E!H:M?^NMO^#]PHZK^NU_^
M >FQ7GFWUQ:_9[A/(5#YKIB.3=GA3W(QSZ9%6:\PA\*ZA)=>(5N_#YCM[R*S
M95MW@:.62)/F&UV^8;L#$@&1U(ZUUWAN\OE;^R+O2HK065I!^]@F#1EBOS(%
MZKMP.N<@BBW]?>*[_KY'0T444AG/^!/^2>>&O^P5:_\ HI:Z"N?\"?\ )//#
M7_8*M?\ T4M=!0 4444 %%%% !1110 5S]G_ ,E#UG_L%6'_ *-NZZ"N?L_^
M2AZS_P!@JP_]&W= '04444 %%%% !1110 4444 <_>?\E#T;_L%7_P#Z-M*Z
M"N?O/^2AZ-_V"K__ -&VE8G@+QV-?MXK#4RL>J!,HW1;A1W'HWJ/Q'LU%M7(
ME.,9*+>K.[HHHI%A1110 4444 %<_>?\E#T;_L%7_P#Z-M*Z"N?O/^2AZ-_V
M"K__ -&VE '04444 %%%% !1110 5S_@3_DGGAK_ +!5K_Z*6N@KG_ G_)//
M#7_8*M?_ $4M '05R%W\0K#3]8N["]TO4H([2:*&>[80F%#*<1L<2%L-_N\=
M\5U]<#:>&&U+XB:SJ.L:)>"R8P/9R272^2[Q C+1)*<G)!4NO&.QH7Q:[ _A
M9U6A:[!K\%U+!!/!]ENI+21)PN=Z'!QM8C'XUJ5Y5HOA_P 0V?C*/4&T&XBA
M-[J,DDIN( &CEVF,';(6QE>F#@\XJ+2?!NKI%JR7V@_9[2]M[67['!-#(IN$
M+EP0[$2$_*"7/S9Y;/06U_+_ "&UJ_4]:K UWQ?I_A[4;"SO8+YA>2K%]HAM
MR\,+,<+YC]%R>!U/X5S&F>%-8_X3&PU#4(Y8(+>S@$ LGA\F!E4K)$V\&3:<
MY 0X..>@-;GBJXUMM0TZTT_PO_:MGYJRS7$EY%"D+!AM.ULLVT_-@ =!@]:=
MM5ZD]&:]WKUC9:]I^C3,XN[Y9&APOR_(,D$]B1G ]C5;Q-XFB\,6UM<3Z?>W
M:7$Z6Z_9?+RKN<*#O=>I.,C/OBN5\5:1K^J/#KEC8ZI_:.GZBCVNGF6T$4B*
M<%R^=P#(6&-_!/W>]:?CRTU75M$TE-/T:ZN)DO[:[EB66%3$L;!F!+2 $]A@
MD9[]Z2V5^_X:?H/K\O\ /];%U?&UK_;EWHLNFZA!J,$!GBAE\H?:@!DB)O,V
ME@",@D8SZ55?Q^D=^;-_#>MB1;1;U]HMVV0DXW868DX.> ">. :AUOP_=>*+
M:_(L[G2]1MKA;G3+R5XCB01A?X'8[3@A@<9!JI):Z_9^,7O;?P[=7,/]CQV"
MRBXMU3S=VXDYDW;!G!.TG@X!XI:V\_\ @.W^7_#C_K\5_P %_P##'7G7M._L
M!=<2<26#1"9)$&=RGI@>IR*ET_4#?(V^SN;25 "\-P%W+GIRK,IZ=B:P]&\,
MMHWP]M?#LL,.H,D BGCE.(Y-S9<9/;EL?05RTW@S4ETE([2PO'L[35+6ZLM.
MOKB.6:!(V_>!'+D!2.BE^F>F<53MS-="=;)_U_7^9WU]KMO8:[IFDRP3M+J/
MF>5*@78I1=Q#<YZ=, UJ5Y+9^#-531-$@NO#XECT^:_\VR,D)WI,2(]H+;2/
MF!P2,!3WP#0UGP)XD:S:!=,?4+Q-!M[5;Q9HANN4F#9!9PV57HQ':@?4]@N[
MS[*]LOV>XF\^419A3<(\@G<WHO'7W%6:\DM?"FL6>L6GV?PU)%8VOB 7D 22
MW"PVYA"/M'F9 +_,5'UQFK\W@ZX;2]1M5T!70W"W$*R>0YGDPV?-!(6506 W
M-M?C/55)/Z_(/Z_/_@'H<%YY]W=6_P!GN(_L[*OF2)A),C.4/<#H?>K->5GP
MMK3:CJ\CZ%_H$VI6]U+9J\#)?1K#L=0&?'W\-\^W/UK-USP3XBN+&PC.D/J%
MW%HUU;-<++"-DCL#$A+."=@'7D#J*0?U^1ZWJ=]_9NG37AMIK@1(7,<.W<0!
MDXW$#IZD5ER>+;(VNG/:6UW>7.HP?:+:SA15F:/ )8AV55 W#[Q'7'-,U.*>
MZ\-6=G>>'GU2*X1([VT>6+?&-O)^9MK$,!T;W!.*YJ73;SP*FG^(YH[G4[?3
M]+>SO8XF#S)&'#JZ[B VW[IYS@ ]J'9-W_K?_@ KM*RU_P"&_P""=2?%MD+:
M.46MZS_;$LIX4AW26TC8QY@!X7D?,"1R",@U'8^,;#4/$-]HD5I?I>6L1F3S
MK?RTN4!P6B9B PR<9.!Z<<U3\%V0O?[0\33)&/[9G2[MXMPD\J-8PB$D9&\C
M).#QG&3BEL+O7IO%U_/=^$VM[.*!H[>^-["\DRJ<A%C!^7<23EFQP,XIM6=G
M_6G^8;JZ-CP]KT'B/21J%O;W%NGFR0M%<!0ZLCE&!VLPZ@]":U:\XT:SOM-\
M&K;:MX:N'F76?/CMWNXE)#W!D5U*.<E002IZD$<CFO1Z'_7W(.O]=V%<_P"!
M/^2>>&O^P5:_^BEKH*Y_P)_R3SPU_P!@JU_]%+2 Z"BBB@ KG[/_ )*'K/\
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MCBO^?C-G_A,?%'_0=N/^_47_ ,31_P )CXH_Z#MQ_P!^HO\ XFL:BCV]3O\
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M_P E#T;_ +!5_P#^C;2N@KG[S_DH>C?]@J__ /1MI0!T%%%% !1110 4444
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M)YXZ4ULK]OQ%+R[HY>#Q[K:>,I=%E?2KPIJHL3:6T#I<"(H'\\YE;Y5S@_*
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M9KT+_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%4AG045S_ /PG?@__ *&O0_\
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M /!C#_\ %4<\NX<D>P?\(-X7_P"@'9?]^Z/^$&\+_P#0#LO^_='_  G?@_\
MZ&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\51SR[AR1[!_P@WA?_H!V7_?N
MC_A!O"__ $ [+_OW1_PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q
M5'/+N')'L8MUX0\/)XVTNS71[06\NG7DKQ[.&9)+8*?J [?F:XCP)X-F\2QP
MW-XKPZ1%PQZ-<$=57T7U/X#OCM;KQIX5;QUI-POB71C FF7J/(+^+:K-+:E0
M3NP"0K$#OM/I6S#XU\%V\"0P^)] CBC4*B)J$("@= !NI\UUKJ8U<+3JRBY+
M;4Z"&&*W@2""-8XHU"HB# 4#H *?7/\ _"=^#_\ H:]#_P#!C#_\51_PG?@_
M_H:]#_\ !C#_ /%5!T'045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__
M  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q
M5 '05S]Y_P E#T;_ +!5_P#^C;2C_A._!_\ T->A_P#@QA_^*K#NO&GA5O'6
MDW"^)=&,":9>H\@OXMJLTMJ5!.[ )"L0.^T^E '>45S_ /PG?@__ *&O0_\
MP8P__%4?\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?
M\)WX/_Z&O0__  8P_P#Q5 '045S_ /PG?@__ *&O0_\ P8P__%4?\)WX/_Z&
MO0__  8P_P#Q5 '05S_@3_DGGAK_ +!5K_Z*6C_A._!__0UZ'_X,8?\ XJL/
MP7XT\*VO@7P];W'B71H9XM,MDDCDOXE9&$2@@@MD$'C% '>45S__  G?@_\
MZ&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\50!T%%<__P )WX/_ .AKT/\
M\&,/_P 51_PG?@__ *&O0_\ P8P__%4 =!7F?B-)C\5+>S4:[<VMQIIFDM['
M59H$C?S53S"!*N !U"@YZX/6NL_X3OP?_P!#7H?_ (,8?_BJR#JGP[;Q&OB
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M7D <!3P 2 .33;UO_6[)2LK?UM_F=+X;UNXURVN)+FSBLY89=A@6<R.G .)
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M/P7XLTZV\"^'H'MM9+QZ9;(QCT6\=21$HX98B&'N"0>U;G_"9:7_ ,^NN?\
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M- '045S_ /PF6E_\^NN?^"*]_P#C-'_"9:7_ ,^NN?\ @BO?_C- '045S_\
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M #ZZY_X(KW_XS0!T%%<__P )EI?_ #ZZY_X(KW_XS1_PF6E_\^NN?^"*]_\
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M DT_P_$ZFBN9\)7GBBYDU*'Q,-'\VVE2.,Z6)=F2H8@F0Y)PR]!734#"N?\
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M*VDTE_.503C+(T9&Q0& ^9020!D"E]F_D.RO]QWUK?6E\C/:74%PBG#-#('
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MQVK@M:L]7T7P!*D^M:M>O'K$(M)5O6CN7MWE5 KNK+NW OC) Y!XQP[N^O\
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M'F'D7])T/3]$29;&%U:=]\TLLKRR2-TRSN2S<<<GBM&N?_X3OP?_ -#7H?\
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M_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ0SH**Y__ (3OP?\ ]#7H?_@QA_\
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MOP?_ -#7H?\ X,8?_BJ/^$[\'_\ 0UZ'_P"#&'_XJCVD^[#DCV(O^%?^%?\
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MH/\ OIO\:/\ A7_A7_H#0?\ ?3?XU+_PG?@__H:]#_\ !C#_ /%4?\)WX/\
M^AKT/_P8P_\ Q5'M)]V')'L1?\*_\*_] :#_ +Z;_&C_ (5_X5_Z T'_ 'TW
M^-2_\)WX/_Z&O0__  8P_P#Q5'_"=^#_ /H:]#_\&,/_ ,51[2?=AR1[&#<^
M"_#B>-=+LETJ(6TVG7DLD>YL,Z26P4]>P=_SK9_X5_X5_P"@-!_WTW^-9%UX
MT\*MXZTFX7Q+HQ@33+U'D%_%M5FEM2H)W8!(5B!WVGTK<_X3OP?_ -#7H?\
MX,8?_BJ/:3[L.2/8B_X5_P"%?^@-!_WTW^-'_"O_  K_ - :#_OIO\:E_P"$
M[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*H]I/NPY(]B+_A7_ (5_
MZ T'_?3?XUSGCSPAX?TGP9?WUEIL4%Q$8MLBLV5S*@/?T)KJ/^$[\'_]#7H?
M_@QA_P#BJAN?&/@B\@,-SXET"6(LK%'U"$@E2&'&[L0#3C5DI)MDRIQ::L<C
MX#\!FX:+6M:AQ&,/:VCCKZ.X_D/Q->J5S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %45:LJDN:04Z<:<>6)T%<_>?\E#T;_L%7_\ Z-M*
M/^$[\'_]#7H?_@QA_P#BJP[KQIX5;QUI-POB71C FF7J/(+^+:K-+:E03NP"
M0K$#OM/I69H=Y17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/
M_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5
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MGY,YR >"!QTQ6%'\,K".&"/^V=680B[VDF#)^T?ZS/[KU)(]/IQ2>VG]:O\
MX!2\_P"OZU-?PYXOL?$TL\5K;W=N\444X%RJCS(I 2CKM8\'!X.".XK/T;4M
M3\3ZEJUQ!J#V-IIU])90VZ0HPF9 -S2E@6QN/ 0KQWJ[X>\&V?AN]:ZMKZ]G
M)LX;+9.8RHCB!"'Y4!SR<\]_I4Q\+6Z:K<WUG?WUB+Q]]W!;N@CN&P%W'<I9
M3@#E"I--VOI_7](E7MJ0)XNLAJZZ/+YWGB46CW:!?*^TF/?Y8YW9V\YV[>V<
M\5@^%?'\2Z&Z^(+FX>Y@@NKI[IXD"R0Q3-&<!,?, %XVC.>,\UT#>#--.N_V
MJ)+A6\[[5]G!7RO/$?EB7E=V[;QC=M[XSS659_##2;;*2ZCJ5W"UK/:/#.T6
MUDF<N^=L:G.XY!!&,4*Q6A<_X3[3U\A'L-06XDO4L7M\1%X9'3>F[#D8*\Y4
MGWQS5C3_ !4VH>*3HZZ5>0JMA'>223!%,>\D!67=D'Y2. >?3J:W_" 6)\AV
MU+46N8KY+][DF+?-(B[%##R]NT+QA0/KGFME-#MXO$DVN)+,+F:V6VDCR-C*
MK$J<8R"-QZ''/2C2_P#7;_,E_P!??_D<[XK\9#0?%>@6 O[-(9[E8KNV9U\Y
MED#*C*"<[0P&2!W%7;OQWI]CX@ET>XLK]98I[>%I@B&/,V1&<A\XR"#QD>F.
M:FU7PDFL:-J.F7>L:D8;Z;S6=?)#Q $$(A\O@# P3EACK6=<?#FUN[]KV?7M
M8>=I+:1F)M_F:#.PG]UZDD^N:(VTO_6WY:CEY?UN/UKQE'')JFD0QWUEJ,=E
M<3VUQ)&FUS&O)4$D\$C[R@'MFHO#/C6:^TVPMKO3M0N-1.G6MT\JK"JW'FX!
M9/G'0DYX&,>XS--\.],FO;B\-_J0GG%T"WFHVT3@!P-RGH%&,YQ[U9TCP[%8
MWUA"UI,8]%M?LUE>RS(S3(RKD$*!@C;CD>A'?!';7^M_^ #\OZV*.I^-4:TW
MVT&HVL:ZG!9FY$,,@8F7:1M,F0"1M.0&&X$*:W]'UZ+6I;Q8;2YBCMI#%YLV
MS;(02#@*Q(P1T8*>0<<UE:EX#L]4EDEEU/4DE>:"4O&T6?W)+(.8SD;B3DY/
M;..*U]/T.#3]1N[\7%Q-/<HD;&4KPJ9P. ,\DG)R><9P  +;7^MO^"#\CE?$
M?CBZT3Q!J*)$LME9:))?K&.LLGF!1DXR ,'\R?2K5QJ&K^'AHU[?:I)J":E=
M0VL]N8(U2)I <-%M4-@-CARW'<5<7X?^&DUZXU:/3+>.2YM'M)H8X42)U8Y9
MB N=QS@G/2L>P\.:UIWC"WCOVO-8T"V"MI;&6$?87"E3YH.UI, X5OF([C/-
M$>B?];Z?E_6Y+K;^MBQK</C:U\*O-8ZS;_VC#.\JA[)"UPA?]W 0&VKP0-PR
M3QT.35R\U#4[;X@:%9&\<6E[97#SVNQ"@DCV896V[_XC_%C@<5>\3>&?^$E@
MMX3K>L:8L+E\Z9<+"SG&.6VDX'/ (ZU'-X3CFU[3-6&JZC')IT)AAA7RC&RG
M&[=NC+'=M&3N[<8HCY_UI;^OO!_U]YKV-[]NBDD^S7-OLE>+;<1["VTXW =U
M.,@]Q5JLW1M/N=/BNEN;V>Z,US),GG2;S$K'(0' ^4=AVSCG%:5( KG_  )_
MR3SPU_V"K7_T4M=!7/\ @3_DGGAK_L%6O_HI: .@HHHH *Y^S_Y*'K/_ &"K
M#_T;=UT%<_9_\E#UG_L%6'_HV[H Z"BBB@#"\60>'KK13!XFNXK;3GD )EOF
MM5=NH!8,N>F<9[>U--WX6U31;:Q?4=/OK"Z(MX!)>+-Y[+T"N6)=QC/4G(S6
M5\5[J"U^'.I^=<PP-($2,RL!N;>#@9(R< G'L:Y;7-.MM$CT?5)]=MII]8U^
M"[>YA"Q0@")E#1J688QCDDY)_"DMG?N@?2W9GI$'AS3+>T-L(II4)!WW%S+-
M)QT^=V+<9XYX[5#+X2T6>P2SEMI7C27SA(;F7SM^-I8R[MY)7Y3EN1QTXKS2
MY^(NJOX.TC4+;5]^HBU-S/'%;QF.<+.L;;VP<<$Y5 I'7(& >BU[Q-J^EW6N
MR6EVUY)%9M/:VD2(4B4%%+/A?,#9WD9+*P!P 1BJ?]?U_7F"[?UV.OU#1]&>
MPM!>PQ1VFENES!ES&D!C!VMP0, 9Z\5SD>D?#[2I[CQ0+VR@;55>%]2?5GVS
M!OO!',F ?E_AP1CC&*UO#.HW3>%1?ZSJ-C,JAI/MD-P'C:+J&9]D:Y ZD*!Q
M7F3:QIY^".GB+5;!)%U6-0SRJRHPNM_S#<.B_,1D?+SP.:+:M/R_%V8)Z)K^
MK*Z/2O!>B>%-&TR8^$1;-97$F]Y+>Z-PK.!C[Q9ORS72UP?PZE$]_P")9UDA
MO/.OEE.I6G%M<DH!^[7)QMQ@_,V3W[#O*'T$NH5S_B'_ )#GA/\ ["LG_I%=
M5T%<_P"(?^0YX3_["LG_ *175(9T%>>>$+6QUC3M3U/7A&=:2^N+>>=VQ+:C
M>51(VZHNW;@#&<YYS7H=4GT;2Y-334Y--LWU!!M6Z:!3*H] ^,C\Z%H[@]K'
M%:AXMN[K4+W3)K.%]/FN+G3!$8CY@*0&0R,2V"AZ;=H]<G.*PO"WC*^TGPKH
M=K!;1/:VFGV#3*\;&2?SY#&/+8, NW&>0V>G'6O49-&TN:ZFNI=-LWN)XO)E
ME:!2\D?]QCC)7V/%1Q>']%@-H8='T^,V>?LI2V0>1GKLP/ES[8IQ:6_E_7]?
MH@?^?]?U^IR,_C36K/3_ !-J4L%C-;:-=2VX2.-U=P%0H22Y'&\[NF<9&*?!
MXK\23WNEZ5)96-CJ-Q'-.[78!CE2-DP%$<K[&97S]Y]N.AS73W%MH&A6=[=3
M6MA9V]RV;IA"JB=F./FP/G8DXYR3FH=/B\.ZI:6T%MIUN(K/$L%M/8&%K?DA
M66-U!3H<' ]J(_Y?E_3!_P"9RJ^*M:AE\0.^HZ8ACU<6%E'/;N<8C5L !QO)
MSTRN/F)., 4-,U^#5?&/A3Q)?"WLC<:!<RW$C,%1 '3.6/\ "#GJ>,UZ.^BZ
M5)+)+)IEF\DDBRN[0*2SJ,!B<<D#@'K52Y\)Z!<PB-M&T]2L+0(ZVD>Y(VSE
M5RIP#D\=.323M;^NC7Z@]?Z\U_D<Y\4[2"_T'2&-E9WK_P!K6HB2X V-N< @
MMM;"L.#@'CL:P/#^KWGAT2:;816L$DOB,6<]H4+V]LLD>X+ RE>!C)R!R3\H
MKTF[\/Z-J%G;V=_I5E>6]N (8KFW658\#' 8''%)_P (YH8M;>U_L;3OL]M)
MYL$7V5-D3_WE&,*?<4UI?^NW^7]=4[M+^N_^9S:^*]=7Q<-&;3K>2*S@A;49
MT9413(I.]2\@8*",8",3SR,<YVE^.=<U3^U+:W73+BXACMI[>:")RC1RELX5
MI 9" I(Y0MZ#I7?R:=8RWJ7LEE;O=HAC6=HE,BJ>JAL9 /I59/#VB1Q/$FCZ
M>L;QB%D%L@#(,X4C'*\GCIR:0SF]*U[4]4\;6-NE]:/IS:*EXXCMW'FN[[<J
M2V5Z<9!X)'7FNVJLNG6*W,5RMG;B>&,Q12B)=R(?X5.,@<#@<<59IO\ K[Q'
MB_A[XGW6E^&M+TZ/1HI4L[2*W$C7)4N$4+G&WC.*T_\ A;M[_P! *#_P+/\
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MK5HAXLUD.NF63&416>Y@9;K"G]QC P2, 'YCDGC!]:K?S!]6H_RE#_A4,?\
MT'9__ =?\:/^%0Q_]!V?_P !U_QKJ_\ A'M4_P"ASUS_ +\V7_R/1_PCVJ?]
M#GKG_?FR_P#D>CZU6_F#ZM1_E/$O#FCW_B:\BLK(#>0&GG8?)"OJ??T'>O>=
M T"Q\.:8EC8IA1\TDC<O*W=F/K6)I'@-M"M#:Z7XFUBUA+;F2.*T.6]<M 6/
MXDU?_P"$>U3_ *'/7/\ OS9?_(]/$8B55VZ"H8>-)7ZG045S_P#PCVJ?]#GK
MG_?FR_\ D>C_ (1[5/\ H<]<_P"_-E_\CUS'0=!17/\ _"/:I_T.>N?]^;+_
M .1Z/^$>U3_H<]<_[\V7_P CT %Y_P E#T;_ +!5_P#^C;2N@K@[K0M1'CK2
M8CXLUDNVF7K"4Q6>Y0);7*C]QC!R"<@GY1@CG.Y_PCVJ?]#GKG_?FR_^1Z .
M@HKG_P#A'M4_Z'/7/^_-E_\ (]'_  CVJ?\ 0YZY_P!^;+_Y'H Z"BN?_P"$
M>U3_ *'/7/\ OS9?_(]'_"/:I_T.>N?]^;+_ .1Z .@HKG_^$>U3_H<]<_[\
MV7_R/1_PCVJ?]#GKG_?FR_\ D>@#H*Y^\_Y*'HW_ &"K_P#]&VE'_"/:I_T.
M>N?]^;+_ .1ZP[K0M1'CK28CXLUDNVF7K"4Q6>Y0);7*C]QC!R"<@GY1@CG(
M!WE%<_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\ OS9?_(] '045S_\
MPCVJ?]#GKG_?FR_^1Z/^$>U3_H<]<_[\V7_R/0!T%%<__P (]JG_ $.>N?\
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M86O?[-N[@7%LE\KB=6*C?N\P;\9'&[GCTQ5E= U)T5T\::VRL,@B*Q((_P#
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M[Z&[O'CDL'B2Y'V:4[#+Q'R%Y!]1D#O6EJ6J66DVOVF^G$498*OREF=CT55
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MSQTHCKO_ %I_F$O+^M?\C<7Q'<7VM7EAI&GI=1V$@CO)Y;CR@KE=VR,;6WL
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MH=0\;(>C BC01\R6W_'K%_NBI:]!\-?#/3M7\*Z1J4FI7\<EY90W#(A3:I=
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M )*'K/\ V"K#_P!&W==!7/V?_)0]9_[!5A_Z-NZY#J.@HHHH **** "BBB@
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M@[5DAUJ&_P!$-K9ZA:VKFUMYXF'GJS&0'<2'/W<E\AQ]X]<>K44+16^7Y?Y
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MHF_G-]'=-$L+/::A<6VY%+%01$Z@X+MU]30!L45S_P#PANE_\_6N?^#V]_\
MCU'_  ANE_\ /UKG_@]O?_CU '045S__  ANE_\ /UKG_@]O?_CU'_"&Z7_S
M]:Y_X/;W_P"/4 =!17/_ /"&Z7_S]:Y_X/;W_P"/4?\ "&Z7_P _6N?^#V]_
M^/4 =!17/_\ "&Z7_P _6N?^#V]_^/4?\(;I?_/UKG_@]O?_ (]0!T%%<_\
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M (]0!T%%<_\ \(;I?_/UKG_@]O?_ (]1_P (;I?_ #]:Y_X/;W_X]0 >!/\
MDGGAK_L%6O\ Z*6N@KFX/ VBVMO%;V\NLPP1($CCCUN]544#   EP !QBI/^
M$-TO_GZUS_P>WO\ \>H Z"BN?_X0W2_^?K7/_![>_P#QZC_A#=+_ .?K7/\
MP>WO_P >H Z"J2Z59KK#ZKY(-Z\0A\T\E4!)P/3D\^O%9G_"&Z7_ ,_6N?\
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M#YN0"54D=]H]*D_X0W2_^?K7/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\
MQZC_ (0W2_\ GZUS_P 'M[_\>H Z"BN?_P"$-TO_ )^M<_\ ![>__'J/^$-T
MO_GZUS_P>WO_ ,>H Z"BN?\ ^$-TO_GZUS_P>WO_ ,>H_P"$-TO_ )^M<_\
M![>__'J .@KG[S_DH>C?]@J__P#1MI1_PANE_P#/UKG_ (/;W_X]49\#:*UP
MEPTNLF=$9$D.MWNY58@L ?-R 2JDCOM'I0!TE%<__P (;I?_ #]:Y_X/;W_X
M]1_PANE_\_6N?^#V]_\ CU '045S_P#PANE_\_6N?^#V]_\ CU'_  ANE_\
M/UKG_@]O?_CU '045S__  ANE_\ /UKG_@]O?_CU'_"&Z7_S]:Y_X/;W_P"/
M4 =!7/\ @3_DGGAK_L%6O_HI:/\ A#=+_P"?K7/_  >WO_QZHX/ VBVMO%;V
M\NLPP1($CCCUN]544#   EP !QB@#I**Y_\ X0W2_P#GZUS_ ,'M[_\ 'J/^
M$-TO_GZUS_P>WO\ \>H Z"BN?_X0W2_^?K7/_![>_P#QZC_A#=+_ .?K7/\
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+< #K0!8HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>table_1.jpg
<TEXT>
begin 644 table_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *D! (# 2(  A$! Q$!_\0
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M_B:\JHH^H4^[#Z]4[(]5_P"$PT'_ )__ /R"_P#\31_PF&@_\_\ _P"07_\
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M /Q-'_"8:#_S_P#_ )!?_P")KRJBCZA3[L/KU3LCU7_A,-!_Y_\ _P @O_\
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M0P!ZX(S0L'1ELV#Q=:.Z1ZQ_PF&@_P#/_P#^07_^)H_X3#0?^?\ _P#(+_\
MQ->5457U"GW9/UZIV1ZK_P )AH/_ #__ /D%_P#XFC_A,-!_Y_\ _P @O_\
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M #__ /D%_P#XFC_A,-!_Y_\ _P @O_\ $UY511]0I]V'UZIV1ZK_ ,)AH/\
MS_\ _D%__B:/^$PT'_G_ /\ R"__ ,37E5%'U"GW8?7JG9'JO_"8:#_S_P#_
M )!?_P")H_X3#0?^?_\ \@O_ /$UY56 GBE)-1N;"/2=0>YMEW2H/*X'K_K.
M>HZ5,L'1CNW_ %\BHXNK+9+^OF>Z?\)AH/\ S_\ _D%__B:/^$PT'_G_ /\
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M /Q-'_"8:#_S_P#_ )!?_P")KRJBCZA3[L/KU3LCU7_A,-!_Y_\ _P @O_\
M$T?\)AH/_/\ _P#D%_\ XFO*J*/J%/NP^O5.R/5?^$PT'_G_ /\ R"__ ,31
M_P )AH/_ #__ /D%_P#XFO*J*/J%/NP^O5.R/5?^$PT'_G__ /(+_P#Q-'_"
M8:#_ ,__ /Y!?_XFO*J*/J%/NP^O5.R/5?\ A,-!_P"?_P#\@O\ _$T?\)AH
M/_/_ /\ D%__ (FO*J*/J%/NP^O5.R/5?^$PT'_G_P#_ ""__P 31_PF&@_\
M_P#_ .07_P#B:\JHH^H4^[#Z]4[(]5_X3#0?^?\ _P#(+_\ Q-'_  F&@_\
M/_\ ^07_ /B:\JHH^H4^[#Z]4[(]5_X3#0?^?_\ \@O_ /$T?\)AH/\ S_\
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MR;?,7&X<=>F,_A7,J3?,WW=ONL;NHK12[6?WW/+;*ZNM-\"65[:W4T<HU J
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MA+7*UU7@#_D/3_\ 7LW_ *$M88G^#+T-L/\ Q8GH]%%%>$>V</\ $3_F&_\
M;7_V2N&KN?B)_P PW_MK_P"R5PU>WA/X*_KJ>-BOXS"BBBNDYPKE_'B2W/AU
M[.WM[B>>1U*K# [\ @G) ('XUU%%9U(<\7'N73GR24NQFZ-:6,-E'+:6*6S,
M@#_Z-Y+$CU! -8F@K*GC+7)9+6ZCCN"GE2O;NJMM&#\Q&/\ &NMHIN%Y)]OU
M!3LFNYR$EG<Z9X@UNY>WN)HM0@ A:&(O\X&-IQT^IP/>LJ^T]= \&Z.=02<7
M-K<>8KPJ'$3$EOF!(!'0=1SWKT2JE[I\=ZT+F26*:!BT4L9&5)&#P00>/4&L
M94++W=_^#<UC6U5_ZTL<?X<UG2;Z?5IXGNI-2N8B\@:#&Y0, (JEO4=R:U/
M\<UKX6CMYK6>&>)GW1S1-&3DDC&1S6W;Z<L,ZW$T\MU<*I199@H*J3D@!0!V
M':KE53I-:M]+?C<FI43NDCS>ZL]4O--L+F73)XI(]2WO;0P%5B3/4*!SZEN:
MU]3BG?XBZ5=I:W36T4)1Y5@<JI(;&3C'<?2NQHH5!*VO5/[E8;KM].C7WGG%
MM!=+H?BB(V%\)+J=G@4VLF7!)QCY:[+PV'7PYI\<D<D4D<*HR2(48$#!X(S6
MK13I4O9]>B7W7_S)J5>?IUN%%%%;&04444 %%%% !1110 5D>)F/_".WL213
M2R30M&B11-(2Q!QPH./J>*UZ*B<>:+CW*C+EDGV//A'<'X8-IOV&^^V* AA-
MK)G)DW<?+R,#K3U2X;7?"\HLKWR[:V$<S&UD 1BN,'Y?6N^HK/V/O7OV_"_^
M9K[?1JW?\3AK>PO-/M/$VG/:7$DET9);>1(R5D# \;N@(]#S5&\LK^+PYX=M
M'TZ\\ZUN0\JI"9,*"><KGUZ=?:O1Z*7U=)63[?@[A[=WO;^K6.2LX;O2/&=_
M<RVUQ+9:BJLDT<3/L8=F &1WZU9U8WT_B+3XDL'6V,3F2Z2,%U.#\F_^ 'C.
M#SZUTE%5[+W>6^G_  _^9/M=>:VMK'GFGZ3J!^'6I::;.=;OSF(C="I894_+
MGKT/2IO$,-S<>$]#@AL;QYHGB9T6V<E0J8.1CCD]^M=[14^P5K7[?@7[=WO;
MJW]YR+6TVG>*K_5&M[F:VOK4+&8H69E< ?*5 R.G4@#UK#O]$U"R\"6&GFUG
MFNS=><T<,32;!SU*@@=17I5%#H+O_5[_ )BC7::=OZM8XZV$K_$1[P6EV+9[
M,1B5[9U7=P<$D<?C1IVESZ?XC@DTN.[MK2X#/>VLJ'RXR1QM;H3GL"<>W2NQ
MHJE12L[[-O[Q.J[6MTM]P4445L8A1110 4444 %9DVN6R7[V-M%->7<8!DBM
MP#L'^TS$*/IG-:$N\1/Y?W]IV_6N+^&QW:?J+39-V;H^<6^]T[_CFLI2?.H+
MM<UC!<CF^ECI9-:AB6<-;W(F@A\YX=@#;?8YVGOT/:JR>*;%]&M=4$5SY%S*
M(47RP6!+$<@'IQZU>U5$.F7DFT;Q;2*#[8_^L*\[$]Q:> -"FMKF>"0W9C)B
ME9 REFR" <'H.M1.I*,FO3\96_(NG3C.-_/]&SU&JVH7L6FZ?/>3*[1PH78(
M,L1["N8N6G;XB+9"\NUMI;,R/$L[A=W(R!GCH.F*S+/4KZZ^'.HW$MY<?:+:
M5ECF65E? *XRP.3U/6E+$:2LMK_@[!&AJKOM^)WUM.EU;17"!@DJ!U##! (S
MR*EKB$U2YN;OPUI4ES.D5U:":>19"KRG;P-X.1R.<&M+4([W2=)MHY-8#)]I
M D>;<))(STC4KEBWOU/M6GM-[+1:?U]Y#I6:5]_^#_D;UY<BSLYKDQO((E+E
M(\;B!UQD@?K4&D:I!K6F17]LDBQ29P)  W!([$^E<QI%]<S#Q/8RRS/!:JWD
MK.Y=T!5N"Q))Z>IK1\!?\B;9?5__ $,TJ=3GEY6O^+14Z7+%WWO^ESI****V
M, HHHH *ANIVM[=Y5@DG*C/EQE=Q^FX@?K4U1S_\>\G^Z?Y5,FU%M#CNC+T+
MQ#!X@B>:UM+J.!25\R8( 6&.,!B>_IBMBN-^&G_(M2_]?3?R6NRI4VW!-]47
M5BHS<5T"BBBK,PHHHH **** "BBB@#,UO6HM"L_M=Q;7$L .'>'8=G( R"P/
M.>V:JW7BB*ST:/59M-OEM7 .?W1(!QM)&_OG_'%5?B!_R)UW_O1_^ABJ'B3_
M ))?#_UPM_\ V6N6I4E'GL]DCIITXR4+K=V.LTZ^_M&RCNA;S0)( R"7;DJ1
MD'Y2?\:M50T/_D :=_U[1_\ H(J_75L<[W"BBB@04444 %%%% $-U.UO;O*L
M$DY49\N,KN/TW$#]:R-,\41:Q937=GIM\\,1()/E L1C(&7]#FMF?_CWD_W3
M_*N-^'7_ "*5U_UWD_\ 05K"<I*=D^C9M",7#F:ZHV=,\41:Q937=GIM\\,1
M()/E L1C(&7]#FI="\0P>((GFM;2ZC@4E?,F" %ACC 8GOZ8K!^'7_(I77_7
M>3_T%:D^&G_(M2_]?3?R6E3G)RBF]U?\BZE.,5*RV=CLJ***Z#F"BBB@ HHH
MH **** &R2"*)I&#%5!)"J6/X <G\*\[TK1(]5N=?MM0LKN%;N<RVTTEJZXP
M6.02..HX/6O1J*RG24W=^?XFL*K@FEUM^!Q.@7^IS:7/HFI6E^C[&A@O#;2!
M6!! ))&1]3^-'A71HULX+74["]6^L92R%Y)?)ZY#)SL[]!7;44HTK--N[0W6
MNFDK7.8U'2+A?&%I?6F%BNHFAO/=0,@_4],UT]4=.TJ'3%D6&25U=V<"1L[-
MQR0..F>><U>JJ<>5>I$Y<S]#CQ:7.C^.[O5);:>6RO(0HD@B:0HPV\%5R?X>
MN.]="Q::*[N-C(C0[4WJ58X!.<'D=>_/%7ZBN(?M%M)#YCQ[U*[TQD9],@C]
M*GV=H.*\_P ;_P"93J<S3?E^!YMI\4^H?#>+2[6VGDN)Y\*1&2@ ?));H/QQ
M6]<65YI'BZSU,037-FUJ+:5H4+M&1WVCG'3I[UNZ)HL.@V7V.WN)Y8=VY1,5
M.W/7!"C]:TZF-'9MZZ?@K?YERK:M)::_B<QKME<2ZWHVKQPRO!:NPE1$+.%(
M^]M')^@&:IV^GW2Q^)]2:"94OD*V\7EMYC#:0#MQD9)Z$9KLZ*;H)WUWO^*L
MR56:2T[?@[GF+VEZ/!NAVO\ 9]\9X+TR2QBUDRJ@DY/'^T/\@UKSF4>.;N]^
MQWIMFL#$LBVDA!;&<?=KMZ*3H>?]6L5[?R[_ (NYY@;.]_X5LFG_ -GWWVL7
M.3%]EDSC.<].F*VXA-)X_L[P6EX+;[$(C*UM(JACDX)(XZUVE%"H6:=^WX*P
MG7NFK;W_ !_X8\HNM3TBSGO]&N/M\-B]X9)81 I;(/9RXPIP#C:3[UZ=:W5O
M-IL5U;EFMC&'3:I)*X].N?;K52+11 #'!?7<5L2Q,"["IW$D\E2W4^M:$$$5
MK;QP0H$BC4*JCL!11IR@FF%:I&=K'(^(=/DUOP\ES8PW"WUE,9(@\#QL?FR0
M P!/&#^%1^,+6ZD\+0V:V]Q<WTDJS2^1;NPSSNY ('H 3TKMJ*<J"::OO;\/
M^&01K--.VQQ/B1I;R;P]+;V=[(D%PLDN+23**" <C;GL>*B%C<WOBOQ$JV]U
M%'>6AAAG>!U0L% ^\1CL?K7=T42H*3;;WO\ BK JS2LE_5[G'>%M)B^QVB7]
MA?1ZA8,<>=)+Y8_VDYV=.PHM],GLO$UM<Z5'=VT=RY>^MI$/E <_,&Z9SV'/
MTZ5V-%-4DK>7]?\ #DNJVWYG%Z+I5V%\36$\$L+7<TACD9#L*L#@ANAZ]!S5
M,:5?7FC:'H_V6>*XLKD/<.\9"*H)Y#]&SGC!/X5Z!125!))7VM^#NBG7=V[?
MU:QPS+/'XTUNZ-G>F"6S,4<@M9"&8!>!@<]#]:STT;4;KX?6=O%:7"W=G=&5
MX'1HV89/3.,]0>/YUZ314_5U:U_ZO?\ ,?UAZ67;\%8YN/2],N=/GN!IE[(;
MM%CG2YDE\PC(X_>'/R]<^W%)X5L[RPEO;4RW,NF1E1:FY0JX_O  @' ^F/2N
MEHK54TI<R,W4;BXL****T,PHHHH *ZKP!_R'I_\ KV;_ -"6N5KJO '_ "'I
M_P#KV;_T):PQ/\&7H;8?^+$]'HHHKPCVSA_B)_S#?^VO_LE<-7J^MQ1SWMA'
M+&DB'S,JXR#P.U5_[*T[_GPM?^_*_P"%>E0Q*ITU%H\ZMAW4J.29YA17I_\
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MR\R>6\^5WX]N-H_ 5CMX*LGTFVTTWU]]FMY3+& T>0WUV>Y_/Z5[I_96G?\
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MU/.:*]/_ +*T[_GPM?\ ORO^%']E:=_SX6O_ 'Y7_"E]=CV']3EW/,**]/\
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MJ>1R#UYH TJ*** "BN>_X2V)Y8/L^DZK=6MQ)Y45Y;0+)$QW;23AMRJ.268
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M?0U8KB.P**** "JEO_R$;S_@'\JMU4M_^0C>?\ _E5+9DO=%NBBBI*"BBB@
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MY+(-V%R2<@8!SR#4+Z)#X?\ [2UC0M,FO-4N0&>!]0D43G(Q]]BJX'3C@<#
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M+#<QVJ&-+BX>X:/S6<*S=<%NF3DX&!DFA:)+R&]V:5%%% @IEE_R'C_U[?\
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M=IC;PJ,*AD8DLW R<]:[*JZ)/?\ K_@$O=VV_P"&_P""%%%% !4-U_QYS_\
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M,\ ,EE(?W\'I_M+Z'_/T]-LKVWU&TCNK6020R#((_D?0UY;4NE:K<>'+PSP
MR64A_?P>G^TOH?\ /TX\1A^;WH[G70K\ONRV/5:*KV5[;ZC:1W5K()(9!D$?
MR/H:L5YQZ 54M_\ D(WG_ /Y5;JI;_\ (1O/^ ?RJELR7NBW1114E!1110 4
M444 %%%% $-U_P ><_\ US;^5%K_ ,><'_7-?Y477_'G/_US;^5%K_QYP?\
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M(<X?YP,KP?F&1P>:\VO)YY/#VOVR:3K)EN->2YB7^R[CYXO,C;</DZ81O?\
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MUUXFU&VO[2[*:?"VKS228\I2H6)G/F98G@JWI3E[K:%%<RN>L45YOI,VK_\
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M>B7$?]G/J6G6[V4L1N'\J>%F#9#^7E&!']TC^BMX-UDV6H@W5@TTFKIJEM&
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MB+_OL56@N(1?W;&:,*VS!+#!XJDG9DMJZ+]%0_:K?_GXB_[[%'VJW_Y^(O\
MOL5-F5=$U%0_:K?_ )^(O^^Q1]JM_P#GXB_[[%%F%T345#]JM_\ GXB_[[%'
MVJW_ .?B+_OL46871-14/VJW_P"?B+_OL4?:K?\ Y^(O^^Q19A=!=?\ 'G/_
M -<V_E1:_P#'G!_US7^517-S UK,!/&248 !QSQ1;7,"VL(,\8(1007''%59
M\I-US%NBH?M5O_S\1?\ ?8H^U6__ #\1?]]BILRKHFHJ'[5;_P#/Q%_WV*/M
M5O\ \_$7_?8HLPNB:BH?M5O_ ,_$7_?8H^U6_P#S\1?]]BBS"Z)J*A^U6_\
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M"Z)J*A^U6_\ S\1?]]BC[5;_ //Q%_WV*+,+HFHJ'[5;_P#/Q%_WV*/M5O\
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M\*L44<S[ARKL5_[/LO\ GTM_^_8_PH_L^R_Y]+?_ +]C_"K%%',^X<J[%?\
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M$BK&-J^9LCP"XY(8X]<Y'4^%9]<GTAO[?M'M[N.9T0R&/=+&#\CL(V90Q'4
MXR#T%4;_ ,!Z=J.AV&FSWVIK)I^/LE_#<>7<PX7;\K* /N\=.>IYYK9T;2(M
M$TY+.*YN[HKR\]Y.TTLA]68]?Y#L*MM-M_UO_2(2LDCSRPGU/3?#'BS6-/U
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M2/0_^@SIW_@4G^->-_9+?_GBGY4?9+?_ )XI^5']GK^8/KS['LG_  D>A_\
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MTJ#4IK&2=Y +.X%PB*1M=@I W<<@9R.G(%7JA;#84444 %5]0_Y!MU_UQ?\
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M@@@@]Q379_TM?R&_+^G_ %_F<=JEYJVD7GBK0;;5-06VMM(&IV5RTHEF@(W
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M/+30(C29[ ;U9<>N0?PKB-7U;Q##\.M<U'^U9+>]TJ6<07<$,6+I(S@%U=&
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M]4HJKIMI]ATVWMB\CM&@#-+,\K$]\NY+'GU-6J3W!:H*\0O?^1BUK_K^E_\
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MW>:%>6MIJ#Q-!/)+ RXC3:<A9"PR>1Q]<5T>JZWIFAV$M]J=]#:VT1"O)(W
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MN0J/Q@C]YV(R/0Y(QDUU5% $#VD;V1M"TPB,?E[EF</C&/O@[L^^<^]<_:^
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M_7]+_P"AFN[ ?&SBQWP(;1117K'EA1110 4444 %%%% !1110 4444 %%%%
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M0:K$ L=C:RVK2)QYK.R_+D=0FT_BWJ#4T?AP1VUV#JNH/?748B?428Q.J#.
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MQ?L[1DR39W;W,B-DY)/8<].F(Y? =C=7^K75YJ&H7(U,)YL3M&JQM&<QLA5
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M)YP2:JZ7K^N_VGK^FP27FHM;Z?%>6+7\$<,SN^\;=JA!MRHP&"G.<\8K4O?
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M--D6W^R0I?1K',PW$LQ4$X'89.>6['G2\3>'HO%&B2Z5<7EW:P2D&1K4H'8
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M:SO^9D_[=/\ V>KAU]"9=/4T:***@HSKS_D,Z;_VU_\ 0:T:SKS_ )#.F_\
M;7_T&M&KELOZZDQW84445!04444 %%%% !1110 4444 %%%% !1110 4444
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MY/O71Q1K%$D:EBJ*%!=BQP/4GDGW-%]+?ULO\AOI_74?1112 **** "BBB@
MKQ34K:]C\2:N!IU[)YEW+(NR!CE=YY^GO7M=9W_,R?\ ;I_[/6^'JNFVUV,*
M])5$DSR#R-0_Z!&I?^ S4>1J'_0(U+_P&:O<**Z/K\^QC]1AW/#_ "-0_P"@
M1J7_ (#-1Y&H?] C4O\ P&:O<**/K\^P?48=SP_R-0_Z!&I?^ S4>1J'_0(U
M+_P&:O<**/K\^P?48=SP_P C4/\ H$:E_P" S4>1J'_0(U+_ ,!FKW"BCZ_/
ML'U&'<\/\C4/^@1J7_@,U'D:A_T"-2_\!FKW"BCZ_/L'U&'<\->.]C0N^E:@
MJCJ6MR!3O(U#_H$:E_X#-7K^N_\ (&N/^ _^A"M&G]>G:]B?J4+VN>'^1J'_
M $"-2_\  9J/(U#_ *!&I?\ @,U>X44OK\^Q7U&'<\/\C4/^@1J7_@,U'D:A
M_P! C4O_  &:O<**/K\^P?48=SP_R-0_Z!&I?^ S4>1J'_0(U+_P&:O<**/K
M\^P?48=SP_R-0_Z!&I?^ S4>1J'_ $"-2_\  9J]PHH^OS[!]1AW/#_(U#_H
M$:E_X#-3?+O?,\O^RM0WXSM^SG./7%>Y5G?\S)_VZ?\ L]-8Z;OH2\%!=3R#
MR-0_Z!&I?^ S4>1J'_0(U+_P&:O<**7U^?8KZC#N>'^1J'_0(U+_ ,!FH\C4
M/^@1J7_@,U>X44?7Y]@^HP[GA_D:A_T"-2_\!FK8\.^$;O7;SSM2@FM=.A;F
M.12CS'TQV'O^7MZQ143QLY1M:Q4,'"+ON,BBC@A2*)%2- %55&  .PI]%%<9
MUA1110 5G6?_ "&=2_[9?^@UHUG6?_(9U+_ME_Z#5QV?]=29;HT:***@H***
M* "BBB@ HHHH KZA_P @VZ_ZXO\ R-&G_P#(-M?^N*?R%&H?\@VZ_P"N+_R-
M&G_\@VU_ZXI_(5?V/G^A/V_E^I8HKE/%]K=7-WIQLHM.OYX1)+_9=^VU;@#;
M\Z-@A70XP2#]X].M<5?:M9:C=6%GJ%[I6F:5-IRR6L?B&V-PK2!W$F'\Y%#K
M\F&))(.0>N8+L>P45Y6E]H]G=:+H_BO6K/5-&?3&^S7MX MM=2K)@EBQ*DA-
MNTECGD@Y-:$$&DW7B#1]"GF35/#LFG2-9&YD$\5S*)!D$GARJ8V]>,GMFG;M
M_6_^1-ST2BO(-5MI!X=:!YYVLK3Q1!#ISBY<9A,J;EX/S!6+J,YQMXZ5:UBX
MF\/:MXVCT6,6\:6%I<LD"[=C.SK+* /XM@R3UX!HMI?^MD_U'_7XM?H=U<^(
M3;>+[#0&L)<7D$DR71==GR8RH&=V>1U '/>C6_$)T;4]'LS82S)J5S]F$ZNH
M2)L$\C.XY /08XY(KDY8=!TCXD>$SIQL[:&ZM+HJ8W $S-Y>UNOS,W//);'?
M%:GCQ4DU+PC&YX;6D& V"?W4GI0EMZ_J'?TO^!V=9OB#5FT+0+W519RW@M8C
M*T,3*&*CDG+$#@9/KQP#7GIFL-+D\6Z:8G2P_M>SB@M+9A%'OE6,E3P0L;-]
M[CH6XR:BM573M,^)&G V=O;06^8[:T&R&$M;DL%7MSUP!D\X%3+X;KM?\O\
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M=_S,G_;I_P"SUHUG?\S)_P!NG_L]7#KZ$RZ>IHT445!04444 %%%% !1110
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MY?\ !_S#OY_\#_(XWQ5IMCHWP]UK3])TV5%O()4AM+"R=QYCH0 $C4[02.I
M&3R:B_X2">?PK'INDZ-JMQJ;6:PA+FPFM8D;:%):255&!G/RDGC@5V]%)ZII
M]1IVM;H>?6^E'2='T#P-%-JL7DQJ\^H6MBSQAE.X+O:-HQE^?FR %P<$BH9$
MNO"/Q$ANVEUW6+?4[7RKZ8::9/)9#^Z<M!$JGJX(Y89':O1Z*=W>Y-DE8Y3Q
MRFIQ6NEZKIEC)?MIMZMS-9Q'#S1[&0[1W8;L@=\5B^)-6?6OAWJ]S;^%]:L[
MB\VQI;RV!-S,P(^9DCW$  =6Q_+/HM%+^OR_R'_7Y_YGENN!XO$$]Y>>'_%6
MJ:9JL,/DG2[B>%HCMVM'+")(]H[[F'\1!J36-.O#9ZEHEMHU]:6G]AK%8QVJ
M%VF8*X\J6<9QLR,*6&=S<M7IU%)JZL-.S3_KI_D>;:0\Z^-?"_F:;J<:0:&U
MM+*]A,(TD;RR%+[=HX1NIXZ'GBJFL0:IJ15I=,U&.>S\0PR_9K:V98!")?\
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M6=_S,G_;I_[/5PZ^A,NGJ:-%%%049UY_R&=-_P"VO_H-:-9UY_R&=-_[:_\
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MGNRW.LHHHKC.L**** "BBB@ HHHH *SK/_D,ZE_VR_\ 0:T:SK/_ )#.I?\
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M+_4=$O[)H/,TZZ:5DF8J'1HV0X(!Y&[('?&,CK7,W/A?Q//!XSC\G2 == 6
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M._YF3_MT_P#9ZN'7T%+IZFC1114%&=>?\AG3?^VO_H-:-9UY_P AG3?^VO\
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M5V_\6:)IDLL=Y>&,1<2R^2[11M_=:0*5#'(PI.3D8%.UM/ZUM_P OK?^NO\
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M?_OX/\:ROLMO_P ^\7_? H^RV_\ S[Q?]\"CDCYASR-7^T++_G[M_P#OX/\
M&C^T++_G[M_^_@_QK*^RV_\ S[Q?]\"C[+;_ //O%_WP*.2/F'/(U?[0LO\
MG[M_^_@_QJO?7UH^GW*K=0,QB8 "0$DX-4OLMO\ \^\7_? J*YMH%M9B((P0
MC$$(..*:A&XG.5C2L;ZT33[96NH%81*"#( 0<"K']H67_/W;_P#?P?XUBVUM
M UK"3!&244DE!SQ4OV6W_P"?>+_O@4.$;@IRL:O]H67_ #]V_P#W\'^-']H6
M7_/W;_\ ?P?XUE?9;?\ Y]XO^^!1]EM_^?>+_O@4N2/F/GD:O]H67_/W;_\
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M?_OX/\:ROLMO_P ^\7_? H^RV_\ S[Q?]\"CDCYASR-7^T++_G[M_P#OX/\
M&C^T++_G[M_^_@_QK*^RV_\ S[Q?]\"C[+;_ //O%_WP*.2/F'/(U?[0LO\
MG[M_^_@_QH_M"R_Y^[?_ +^#_&LK[+;_ //O%_WP*/LMO_S[Q?\ ? HY(^8<
M\C5_M"R_Y^[?_OX/\:/[0LO^?NW_ ._@_P :ROLMO_S[Q?\ ? H^RV__ #[Q
M?]\"CDCYASR-7^T++_G[M_\ OX/\:/[0LO\ G[M_^_@_QK*^RV__ #[Q?]\"
MC[+;_P#/O%_WP*.2/F'/(U?[0LO^?NW_ ._@_P :/[0LO^?NW_[^#_&LK[+;
M_P#/O%_WP*/LMO\ \^\7_? HY(^8<\C5_M"R_P"?NW_[^#_&C^T++_G[M_\
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M 1F,OB,GAE/!W$=<XZ$<Y?6W]=?\@M_7W?YG<VM];7K7"V\F\V\IAE^4C:X
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M_P"^F_QH_P"$VUG_ )\;/_OIO\:/JU3L'UBGW._HK@/^$VUG_GQL_P#OIO\
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MYC'_ &[_ /LU5'J3+H6Z***DH**** "BBB@ HHHH **** "JEO\ \A&\_P"
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M5]=TW0K);O4;D0QNP2-<%GD8]%51DL?8"I--OWU&W:9K"[LU#E56Z559Q_>
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MI_:O_77_ #)7P\O];6.":[?1M&\4064D-I86FMQQG]T6CMH&6,O\B%3MR3D
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MUB"6-(HYBK$;_D=#M8@C:2W!_A![5)K^@Q3Z?96JZ9<7<5I&?*EL[D0W43\
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M_#\3OX[6"*XEG2,":7&]SR3CH/I[=.M2*B(6*JJECEL#&3ZURNE>-)-0T?\
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M30H.;N]@T+0K;0K+R8?GE?F68CES_A[5J445YC;;NST4DE9!53_F,?\ ;O\
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M6H<M174_\(!#_P!!6[_2C_A (?\ H*W?Z4?6Z8?5:ARU%=3_ ,(!#_T%;O\
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MK?\ (1T__MI_(44:M_R$=/\ ^VG\A16Z^%&+^)A1110 4444 %%%% !1110
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M:3%J;:G'IEDE^V=UTMN@E/&.7QGI[T+0;=]C'\9W+6\.DK*VS3IM0CBOGW8
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M !1110 4444 %5/^8Q_V[_\ LU6ZJ?\ ,8_[=_\ V:JCU)ET+=%%%24%%%%
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M_EP.[R@C(VQJ"YXYQC@5S6A^-5@LKZ;7KUIL:H]G;R6MA(5; 7:NU Q!)/\
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M )\?_(HHY6',@U/_ )!TOX?S%6ZR[Z:Y>SD62UV*<9;S <<CM5G[1>?\^/\
MY%%/E=A<RN6Z*J?:+S_GQ_\ (HH^T7G_ #X_^112Y6/F1;HJI]HO/^?'_P B
MBC[1>?\ /C_Y%%'*PYD6Z*J?:+S_ )\?_(HH^T7G_/C_ .111RL.9%NBJGVB
M\_Y\?_(HH^T7G_/C_P"111RL.9%NJG_,8_[=_P#V:C[1>?\ /C_Y%%5O.N?[
M2W?9?G\G&SS!TSUS3C%ZB<EH:E%5/M%Y_P ^/_D44?:+S_GQ_P#(HI<K'S(M
MT54^T7G_ #X_^111]HO/^?'_ ,BBCE8<R+=%5/M%Y_SX_P#D44?:+S_GQ_\
M(HHY6',BW153[1>?\^/_ )%%'VB\_P"?'_R**.5AS(MT54^T7G_/C_Y%%'VB
M\_Y\?_(HHY6',BW52W_Y"-Y_P#^5'VB\_P"?'_R**K0S7(O;EEM<L=NY?,'R
M\<<]Z:B[,3DKHU**J?:+S_GQ_P#(HH^T7G_/C_Y%%+E8^9%NBJGVB\_Y\?\
MR**/M%Y_SX_^111RL.9%NBJGVB\_Y\?_ "**/M%Y_P ^/_D44<K#F1;HJI]H
MO/\ GQ_\BBC[1>?\^/\ Y%%'*PYD2W7_ !YS_P#7-OY46O\ QYP?]<U_E5:X
MGNC;2AK/:I0Y/F@X&*+>>Z%M$%L]RA!@^:!D8I\KY1<RYB_153[1>?\ /C_Y
M%%'VB\_Y\?\ R**7*Q\R+=%5/M%Y_P ^/_D44?:+S_GQ_P#(HHY6',BW153[
M1>?\^/\ Y%%'VB\_Y\?_ "**.5AS(MT54^T7G_/C_P"111]HO/\ GQ_\BBCE
M8<R+=9FM:+'KEO#!+>W]JD<HD;['<&$R#!&QB.2ISR.*L?:+S_GQ_P#(HH^T
M7G_/C_Y%%'*',6(HD@B2*) D:*%55&  .@I]5/M%Y_SX_P#D44?:+S_GQ_\
M(HHY6',BW153[1>?\^/_ )%%'VB\_P"?'_R**.5AS(MT54^T7G_/C_Y%%'VB
M\_Y\?_(HHY6',BW153[1>?\ /C_Y%%'VB\_Y\?\ R**.5AS(MT54^T7G_/C_
M .111]HO/^?'_P BBCE8<R+=%5/M%Y_SX_\ D44?:+S_ )\?_(HHY6',BW15
M3[1>?\^/_D44?:+S_GQ_\BBCE8<R+=%5/M%Y_P ^/_D44?:+S_GQ_P#(HHY6
M',BW153[1>?\^/\ Y%%'VB\_Y\?_ "**.5AS(MT54^T7G_/C_P"111]HO/\
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M[?\ [\O_ (4?\)UX?_Y^W_[\O_A1[.78.>/<Z.BN<_X3KP__ ,_;_P#?E_\
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M.?85JRRQP1/+*ZI&BEF9C@ #J31?2X=;#Z*BM;B.\M(;F(DQS(LB$^A&14M
M!1110 4444 %,LO^0\?^O;_V:GTRR_Y#Q_Z]O_9J?1^@NJ-JBBBN<W,C5O\
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M44AA4-U_QYS_ /7-OY5-4-U_QYS_ /7-OY4UN)[!:_\ 'G!_US7^535#:_\
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M(L'NPNT3M;(7"XQC=C.,<?2I=.TG3=(B>+3=/M+*-VW,EM"L88^I"@<U2?\
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M0N@GU.JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*99?\AX_]>W_ +-3Z99?\AX_]>W_ +-3Z/T%U1M4445SFYD:M_R$=/\ ^VG\
MA11JW_(1T_\ [:?R%%;KX48OXF5[ZPL]3M6M;^T@N[=B"T4\8D0D<C((Q6:O
M@_PPD3Q+X<TA8Y,;U%C& V.F1MYK:HHL!#:VMO8VT=M:6\5O;QC"11($51Z
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M7KU>7OH&NI?W$<>FA]\CRK^_094GKUKJPLE&3;.7%1<HI(JT5<_X1_Q'_P!
MD?\ @1'_ (T?\(_XC_Z!(_\  B/_ !KN]M3[G'[&IV*=%7/^$?\ $?\ T"1_
MX$1_XT?\(_XC_P"@2/\ P(C_ ,:/;4^X>QJ=BG37=8T+,0%'4FKW_"/^(_\
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M_P"_)HY6',BQ15?[3)_SX7O_ 'Y-'VF3_GPO?^_)HY6',BQ15?[3)_SX7O\
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M57^TR?\ /A>_]^31]ID_Y\+W_OR:.5AS(L457^TR?\^%[_WY-'VF3_GPO?\
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M<R(5YW T-63&G=HVZ***YS<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 4P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD!STZ
M>M "UGZSKFF^']/>^U2[CMK=?XG/+'T ZD^PK&\;^.=/\%:9YT^)KV4'[/:J
M>7/J?11ZUX_HGA;Q+\6M5.LZY=R0:8K$+)C QGE(EZ?C_,UG*=GRK5G70PO-
M'VE1\L?S]#<U?XWZAJ-[]A\(Z*\SL<)),A=V]Q&O3\2?I6IIGB/XC:;ITVI^
M)+*W2W0AD1PBLX[KA3D''(/MR*] T#PSHOA6P^SZ7:1VZ8^>4\N_NS'D_P J
MX+XE^++ K%82W)BM/,59957<0">2!WXZ>V:QK.2C9/WGLEW.O"^RJ55&,%R+
M=O70]0M+E+RR@NH\^7-&LBYZX(R/YU-5#1KW3[[3(FTR426T0\H8R"NT 8(/
M0XQ5^NJS6DMSRI6N[!1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MDC&>,CIZUH_$KQ7H^L?\(K+83S3QVVM0W4CI;28\E<[I!\O*@\9'<''2O9*
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 4P# 2(  A$! Q$!_\0
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M0XQ5^NJS6DMSRI6N[!1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MDC&>,CIZUH_$KQ7H^L?\(K+83S3QVVM0W4CI;28\E<[I!\O*@\9'<''2O9*
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
